<SEC-DOCUMENT>0001144204-16-131864.txt : 20161107
<SEC-HEADER>0001144204-16-131864.hdr.sgml : 20161107
<ACCEPTANCE-DATETIME>20161107083316
ACCESSION NUMBER:		0001144204-16-131864
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20161107
DATE AS OF CHANGE:		20161107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TAPIMMUNE INC
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205757
		FILM NUMBER:		161976656

	BUSINESS ADDRESS:	
		STREET 1:		50 N LAURA STREET
		STREET 2:		SUITE 2500
		CITY:			JACKSONVILLE
		STATE:			FL
		ZIP:			98102
		BUSINESS PHONE:		(206) 504-7278

	MAIL ADDRESS:	
		STREET 1:		50 N LAURA STREET
		STREET 2:		SUITE 2500
		CITY:			JACKSONVILLE
		STATE:			FL
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EDUVERSE COM
		DATE OF NAME CHANGE:	19990827
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>v452346_424b3.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT NO. 3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus Supplement No. 3&nbsp;Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated June 10, 2016 and </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus Supplement No. 1 dated August 15, 2016 and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus Supplement No. 2 dated September 15, 2016)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Statement No. 333-205757</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1094038|000142488415000174|form424b30.jpg" STYLE="height: 124px; width: 243px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TapImmune Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,920,564 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement No. 3 updates,
amends and supplements the prospectus dated June 10, 2016, as supplemented by Prospectus Supplement No.1 dated August 15, 2016
and Prospectus Supplement No. 2 dated September 15, 2016 which form a part of our registration statement Form S-1 (Registration
Statement No. 333-205757 relating to the resale of up to 5,920,564 shares of our common stock by the selling stockholders named
in the &ldquo;Selling Stockholders&rdquo; section of the prospectus. We will not receive any proceeds from the sale of our shares
by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement is being filed
to update, amend and supplement the information included or incorporated by reference in the prospectus with the information contained
in our Current Reports on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2016 (the &ldquo;Report&rdquo;)
including the effectiveness of a one-for-twelve reverse stock split of our issued and outstanding common stock on September 16,
2016 (the &ldquo;Reverse Split&rdquo;). Accordingly, we have attached the Report to this prospectus supplement and the Report is
incorporated by reference into this prospectus supplement. All share amounts reflect the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The attached information updates, amends
and supplements certain information contained in the prospectus. To the extent information in this prospectus supplement No.&nbsp;3
differs from, updates or conflicts with information contained in the prospectus as supplemented, the information in this prospectus
supplement No.&nbsp;3 is the more current information. This prospectus supplement is not complete without, and should not be delivered
or utilized, except in conjunction with the prospectus, including any supplements and amendments thereto. You should read this
prospectus supplement in conjunction with the prospectus, including any supplements and amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is traded on the OTCQB
marketplace under the symbol &ldquo;TPIV.&rdquo; On November 4, 2016, the last reported closing price of our common stock was $5.73
per share. Our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &ldquo;TPIV&rdquo; and
trading is expected to commence on the Nasdaq Capital Market on November 8, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves risks. You should
carefully consider the risk factors for our business, our industry and our securities, which begin on page 1 of the prospectus,
as well as any updates to such risk factors included in any supplements and amendments thereto.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
November 7, 2016&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B><BR>
<B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>FORM
10-Q</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Quarterly
Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended <B>September 30, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition
Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: <B><U>000-27239</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg1img1_10q.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 18pt; text-transform: uppercase"><B><U STYLE="text-decoration: none">TAPIMMUNE
    INC.</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Name of registrant in its charter)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; text-align: center"><B>NEVADA</B></TD>
    <TD STYLE="width: 4%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; text-align: center"><B>45-4497941</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50 N. Laura Street, Suite 2500</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Jacksonville, FL</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>32202</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>904-516-5436</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(Issuer's telephone number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><B>x</B></FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definition of &ldquo;accelerated
filer&rdquo;, &ldquo;large accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act
(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Large&nbsp;accelerated&nbsp;filer</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Accelerated&nbsp;filer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Non-accelerated&nbsp;filer&nbsp;(Do&nbsp;not&nbsp;check</TD>
    <TD><FONT STYLE="font-family: Wingdings"><B>x</B></FONT>&nbsp;&nbsp;Smaller&nbsp;reporting&nbsp;company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if&nbsp;smaller&nbsp;reporting&nbsp;company)</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><B>x</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 2, 2016, the Company had
8,379,101 shares of common stock issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 12%; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="width: 80%; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-left: 0.1in; font-size: 10pt; text-align: right"><B>Page</B></TD></TR>
<TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><A HREF="#TAP_001"><B>PART I &ndash; FINANCIAL INFORMATION</B></A></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_002">Financial Statements (Unaudited)</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">1</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_003">Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">1</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_004">Condensed Consolidated Statements of Operations for the Three and Nine months ended September 30, 2016 and 2015</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_005">Condensed Consolidated Statement of Stockholders' Equity (Deficit) for the Nine months ended September 30, 2016</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">3</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_006">Condensed Consolidated Statements of Cash Flows for the Nine months ended September 30, 2016 and 2015</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">4</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_007">Notes to Condensed Consolidated Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">6</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_008">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;3.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_009">Quantitative and Qualitative Disclosures About Market Risk.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">24</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_010">Controls and Procedures.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">24</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><B><A HREF="#TAP_011">PART II &ndash; OTHER INFORMATION</A></B></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_012">Legal Proceedings.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;1A.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_013">Risk Factors.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_014">Unregistered Sales of Equity Securities and Use of Proceeds.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;3.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_015">Defaults Upon Senior Securities.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_016">Mine Safety Disclosures.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;5.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_017">Other Information.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">Item&nbsp;6.</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><A HREF="#TAP_018">Exhibits.</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">26</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><A HREF="#TAP_019">Signatures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right">27</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTE REGARDING REVERSE STOCK SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 13, 2016, we filed a Certificate of Change pursuant
to NRS 78.209 with the Secretary of State of the State of Nevada to effect a reverse split of our common stock at a ratio of one
for twelve, effective on September 16, 2016. All historical share and per share amounts reflected in this report have been adjusted
to reflect the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><A NAME="TAP_001"></A><B>PART&nbsp;I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><A NAME="TAP_002"></A><B>Item 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="TAP_003"></A><FONT STYLE="font-style: normal; text-transform: uppercase">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal; text-transform: uppercase">CONDENSED
CONSOLIDATED BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September 30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2016</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>December 31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2015</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9,586,773</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,576,564</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">111,652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68,803</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,698,425</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,645,367</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,678,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">967,358</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research agreement obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">492,365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">492,365</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Derivative liability &ndash; warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,493,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Promissory note, related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,204,444</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,005,723</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Convertible preferred stock, $0.001 par value &mdash; 5,000,000 shares authorized:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued&nbsp;&nbsp;and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock, $0.001 par value, 41,666,667 shares authorized, 8,395,768 and 5,882,976 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,884</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,724,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,142,187</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(144,238,988</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(133,508,427</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,493,981</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,360,356</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,698,425</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,645,367</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to these unaudited
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="TAP_004"></A><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal">CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine months ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P></TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,109,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">968,759</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,343,248</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,324,432</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,612,305</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">769,219</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,557,701</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,579,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss from Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,721,637</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,737,978</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,900,949</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,904,186</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">684,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,266,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,925,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,485,585</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Foreign exchange gain</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">775</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Grant income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Loss on debt settlement agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(65,325</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,697</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,640</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,697</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Income (Loss)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,102,962</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">28,503,325</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(878,561</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(32,413,693</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Basic Net Income (Loss) per Share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(10.61</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Diluted Net Income (Loss) per Share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.54</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10.61</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Weighted Average Number of Common Shares Outstanding, Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,281,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,048,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,370,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,054,297</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Weighted Average Number of Common Shares Outstanding, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,281,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,745,416</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,935,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,054,297</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to these unaudited
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="TAP_005"></A><B>TAPIMMUNE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&rsquo;
EQUITY (DEFICIT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Common Stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>shares</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Amount</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paid In</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Capital</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accumulated </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Deficit</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; padding-bottom: 1pt">Balance, December 31, 2015</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">5,882,976</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">5,884</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">112,142,187</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">(133,508,427</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">(21,360,356</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of common stock in private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,134,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,135,196</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finders&rsquo; fee and legal costs relating to private placements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(804,070</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(804,070</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Fair value of shares issued as inducement on August 10, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,499,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,500,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fair value of series F and F-1 warrants issued as inducement in August 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,352,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,352,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,465,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,465,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,999,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finders&rsquo; fee on exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(516,651</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(516,651</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Reclassification of fair value of derivative liabilities at exercise date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,074,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,074,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shares issued in debt settlement agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock- based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,309,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,309,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(878,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(878,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">8,395,768</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">8,396</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">151,724,573</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(144,238,988</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,493,981</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to these unaudited
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="TAP_006"></A><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal">CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine months ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nine months ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September 30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2015</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flow from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(878,561</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(32,413,693</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Changes in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,925,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,485,585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Loss on debt settlement agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,697</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,309,109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261,805</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,849</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,782</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Accounts payable and accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">710,720</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">204,956</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,756,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,492,432</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flow from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Private placements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,135,196</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,464,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Finders&rsquo; fee and legal costs on private placements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(804,070</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(137,986</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Repayment of promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Repayment of promissory note &ndash; related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Proceeds from exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,427,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Finders&rsquo; fee on exercise of warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(516,651</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(316,508</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,766,475</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,437,504</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,010,209</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,945,072</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Cash, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,576,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">141,944</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Cash, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,586,773</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,087,016</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to these unaudited
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal">CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Nine months<BR>
ended <BR>September 30,<BR>
2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months <BR>Ended <BR>September 30,<BR>
2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental schedule of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson&rsquo;s compensation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">191,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable settled in common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fair value of issuance of series F and F-1 warrants as inducement in August 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,352,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Fair value of shares issued as inducement on August 10, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,465,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Fair value of issuance of warrants in January and March 2015 financing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,313,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of additional warrants in May 28, 2015 transaction</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,133,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,074,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,745,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to these unaudited
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="TAP_007"></A><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal">September
30, 2016</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 1:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Nature of Operations</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TapImmune Inc. (the &ldquo;Company&rdquo;),
a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development
of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike
other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates
the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation
in tumor cells allowing their recognition and killing by the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">NOTE 2: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Basis of Presentation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of
America (&ldquo;U.S. GAAP&rdquo;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8
of Regulation S-X of the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and on the same basis as the Company prepares its
annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation
of such interim results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results for the statement of operations
are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period.
The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements; however, it does
not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed
consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December
31, 2015, and notes thereto included in the Company&rsquo;s annual report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">NOTE 3: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">LIQUIDITY AND FINANCIAL CONDITION</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s activities since inception
have consisted principally of acquiring product and technology rights, raising capital, and performing research and development.
Successful completion of the Company&rsquo;s development programs and, ultimately, the attainment of profitable operations are
dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a
customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has
been funded by a combination of equity and debt financings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to continue to incur
substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will
need to complete certain research and development activities and clinical studies. Further, the Company&rsquo;s product candidates
will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures
to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The
Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term,
revenue from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2016, the Company had
cash and cash equivalents of approximately $9,587,000. Historically, the Company had net losses and negative cash flows from operations.
Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings.
Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination
or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable
terms, or at all. These matters raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. The financial
statements do not include any adjustments that might result from the outcome of these uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 4:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">SIGNIFICANT ACCOUNTING POLICIES</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes in
the Company&rsquo;s significant accounting policies to those previously disclosed in the Company&rsquo;s annual report on Form
10-K, which was filed with the SEC on April 14, 2016 other than the one disclosed below relating to grant income:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Grant Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes grant income in
accordance with the terms stipulated under the grant awarded to the Company&rsquo;s collaborators at the Mayo Foundation from the
U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for
reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company&rsquo;s ongoing future
performance. The Company has adopted a policy of recognizing these payments as grant income when received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Accounting Pronouncement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Update (&ldquo;ASU&rdquo;),
No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) issued ASU No. 2016-09, Compensation-Stock
Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions,
including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement
of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including
tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement.
The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur.
An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period.
An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest
(current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15,
2016, including interim periods within those fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated the impact of
ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material
impact on the Company&rsquo;s future financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 5:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">net income (loss) per share</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic income (loss) per common share is
computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted
income per common share is computed similar to basic income per common share except that it reflects the potential dilution that
could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income (loss) per-share amounts for all
periods have been retroactively adjusted to reflect the Company&rsquo;s 1-for-12 reverse stock split, which was effective September
16, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of income (loss) per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended<BR> September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Nine Months Ended<BR> September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income
    (loss)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,102,962</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,503,325</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(878,561</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,413,693</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    Non cash income from changes in fair value of derivative liabilities</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,856,000</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    income (loss) - diluted</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,102,962</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,503,325</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,734,561</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,413,693</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average shares outstanding -
    basic</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,281,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,048,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,370,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,054,297</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,663,333</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">565,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock options</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">33,333</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average
    shares outstanding - diluted</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,281,000</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,745,416</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,935,000</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,054,297</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    income (loss) per share data:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.29</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.04</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.14</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10.61</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diluted</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.29</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.23</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.54</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10.61</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following securities, rounded to the thousand, were not
included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Common stock options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">432,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">39,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock warrants - equity treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,054,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Common stock warrants - liability treatment</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,750,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,492,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,000,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 6:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">DERIVATIVE LIABILITY - WARRANTs </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of quantitative information with
respect to valuation methodology and significant unobservable inputs used for the Company&rsquo;s common stock purchase warrants
that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Share Purchase Warrants</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Inputs for the Period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of valuation</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Nine<BR> Months Ending<BR> September 30,<BR> 2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Nine<BR> Months Ending<BR> September 30,<BR> 2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contractual term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Volatility (annual)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Dividend yield (per share)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing assumptions are reviewed
quarterly and are subject to change based primarily on management&rsquo;s assessment of the probability of the events described
occurring. Accordingly, changes to these assessments could materially affect the valuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financial Assets and Liabilities Measured at Fair Value
on a Recurring Basis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value accounting standards define
fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an
asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either
directly or indirectly; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require
the reporting entity to develop its own assumptions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial assets and liabilities measured
at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &ndash; warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of September 30, 2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Fair Value Measurements</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Fair Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Level 1</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Level 2</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Level 3</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Derivative liability - warrants</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">29,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">29,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">29,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31, 2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Fair Value Measurements</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Fair Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Level 1</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Level 2</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Level 3</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Derivative liability - warrants</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">26,493,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">26,493,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">26,493,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,493,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,493,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,493,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between Level 1,
2 or 3 during the nine months ended September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents changes in
Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 82%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Derivative liability &ndash; warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 81%">Balance &ndash; December 31, 2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">26,493,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reclassification of derivative liabilities to equity at exercise date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,074,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,465,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,925,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; September 30, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Amendment Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2016, the Company and holders
of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series
D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the &ldquo;Amended
Warrants&rdquo;) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously
precluded equity classification treatment on the Company&rsquo;s balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for such amendment and
the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of
common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise
price of $7.20 per share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders&rsquo;
equity of $4.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Amended Warrants
was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $556,000 in the statement
of operations and $15.5 million was reclassified to equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note
    7:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">STOCK-BASED COMPENSATION</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the components
of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended
September 30, 2016 and 2015, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">573,137</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">13,244</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,309,109</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">261,805</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">573,137</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,244</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,309,109</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">261,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Options </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the Company&rsquo;s stock option activity is as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock&nbsp;Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average<BR> Exercise Price<BR> per Share</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average<BR> Remaining<BR> Contractual Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic&nbsp;Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Outstanding as of December 31, 2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">298,679</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">9.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">9.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">177,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">228.00</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding as of&nbsp;September 30, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">432,013</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">271,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercisable as of&nbsp;September 30, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">174,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total stock-based compensation cost related
to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of
September 30, 2016 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: justify">Unrecognized stock-based compensation cost:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,081,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Expected weighted average period compensation costs to be recognized (years):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note
    8:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Promissory note </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2016, the Company had
an outstanding promissory note in the amount of $5,000 as compared to two outstanding promissory notes totaling $30,000 at December
31, 2015. The promissory note outstanding at September 30, 2016 bears 10% annual interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September
30, 2016, the Company paid a $25,000 promissory note and $6,524 of accrued interest in final settlement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note
    9:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Promissory note, related
    party</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2015, the Company had an
outstanding promissory note in the amount of $23,000 owed to an officer of the Company. The promissory note bore no interest charges
and had no fixed repayment terms. In September 2016, the note was paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 10:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Capital Stock</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reverse Stock Split</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective September 16, 2016, the Company
effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common
shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods
presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period
share transactions included in the Company&rsquo;s stock transactions and balances have been retroactively restated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2016 Common Stock Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Private placements</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2016 and August 25, 2016,
the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the
Company&rsquo;s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common
stock for $6.00. The Company issued and sold an aggregate of 653,166 units at a purchase price per unit of $4.80 for an aggregate
of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company issued five-year
warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the registration rights agreements
entered into in connection with the private placements, the Company is required to file a registration statement with the Securities
and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of
common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise
of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the
August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared
effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the registration rights
agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages.
The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase
price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with applicable U.S. generally
accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration
under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it
be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be
required to record would be approximately $29,000 per month for each month it fails or is estimated to fail to meet the above criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the August 10, 2016 and August 26,2016
private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required
to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Amendment Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2016, the Company and holders
of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series
D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the &ldquo;Amended
Warrants&rdquo;) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously
precluded equity classification treatment on the Company&rsquo;s balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In consideration for such amendment and the exercise of the
Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such
warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per
share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders&rsquo; equity
of $4.5 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Share Purchase Warrants</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company&rsquo;s share
purchase warrants as of September 30, 2016 and changes during the period is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number of <BR>Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted Average <BR>Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-weight: bold; text-align: left">Balance, December 31, 2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">4,343,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">8.67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,000,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,718,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance, September 30, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,059,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Consulting Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September
30, 2016, the Company issued 60,000 common shares as part of consulting agreements. The fair value of the common stock of approximately
$414,000 was recognized as stock-based compensation in general and administrative expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Debt Settlement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2016, the Company issued 10,191
common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $70,000 was
recognized as loss on debt settlement agreements in other income (expense).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2016, the Company paid $27,000
for a promissory note from 2008 and related $38,000 of accrued interest. The $65,000 payment was recognized as loss on debt settlement
agreements in other income (expense).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 11:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">grant income</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September
30, 2016, the Company received approximately $231,000 of grant awarded to Mayo Foundation from the U.S. Department of Defense for
the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">Note 12:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="text-transform: uppercase">COMMITMENTs</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employment Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2015, the Company entered into
an employment agreement with Dr. Glynn Wilson, the Company&rsquo;s Chief Executive Officer, President and Chairman of the Company.
As part of the agreement, Dr. Wilson was awarded 19,018 fully vested common shares in March 2016. The fair value of the common
stock of approximately $146,000 was recognized as stock-based compensation in general and administrative expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July, 2016, the Company entered into
an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company&rsquo;s President and Chief Operating
Officer. As part of the agreement, Dr. Bonfiglio was awarded 20,833 common shares, which will vest upon the earlier of (i) the
listing of the Company&rsquo;s common stock on a national securities exchange in the United States or (ii) the first anniversary
of the employment agreement, so long as Dr. Bonfiglio is employed with the Company. The fair value of the common stock of approximately
$103,000 was recognized as stock-based compensation in general and administrative expense.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2016, the Company appointed
Michael Loiacono as the Company&rsquo;s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection
with Mr. Loiacono&rsquo;s appointment he entered into an employment agreement with the Company. The employment agreement provides
that Mr. Loiacono&rsquo;s base salary will be $200,000 per year and he is eligible for an annual performance bonus of up to 50%
of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional
12 months unless terminated by Mr. Loiacono or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_008"></A>Item 2.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This quarterly report on Form 10-Q contains
forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve
risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect
that we &ldquo;believe&rdquo;, &ldquo;expect&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;plan&rdquo;, &ldquo;target&rdquo;, &ldquo;intend&rdquo;
and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those
discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section
and elsewhere in this quarterly report on Form 10-Q, and the risks discussed in our other filings with the Securities and Exchange
Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&rsquo;s
analysis, judgment, belief or expectation only as the date hereof. We assume no obligation to update these forward-looking statements
to reflect events or circumstance that arise after the date hereof.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>As used in this quarterly report: (i)
the terms &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, &ldquo;TapImmune&rdquo; and the &ldquo;Company&rdquo; mean TapImmune
Inc. and its wholly owned subsidiary, GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless
the context otherwise requires; (ii) &ldquo;SEC&rdquo; refers to the Securities and Exchange Commission; (iii) &ldquo;Securities
Act&rdquo; refers to the Securities Act of 1933, as amended; (iv) &ldquo;Exchange Act&rdquo; refers to the Securities Exchange
Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following should be read in conjunction
with our unaudited consolidated interim financial statements and related notes for the three and nine months ended September 30,
2016 included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2015.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Cancer Vaccines</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage immuno-oncology
company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment
of cancer &amp; metastatic disease. We are also developing a proprietary technology to improve the ability of the cellular immune
system to recognize and destroy diseased cells. This DNA expression technology named Polystart is in preclinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To enhance shareholder value and taking
into account development timelines, we plan to focus on advancing our clinical programs including our Folate Receptor Alpha program
for breast and ovarian cancer and our HER2/neu peptide antigen program into Phase II clinical trials. In parallel, we plan to complete
the preclinical development of our Polystart technology as an integral component of our prime-and-boost vaccine methodology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Immunotherapy Industry for Cancer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuno-oncology has become the most rapidly
growing sector in the pharmaceutical and biotech industry. The approval and success of checkpoint inhibitors Yervoy and Opdivo
(Bristol Myers Squibb) and Keytruda (Merck &amp; Co.) together with the development of CAR T-cell therapies (Juno Therapeutics,
Kite Pharma) has provided much momentum in this sector. In addition, new evidence points to the increasing use of combination immunotherapies
for the treatment of cancer. This has provided greater opportunities for the successful development of T-cell vaccines in combination
with other approaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Products and Technology in Development-Clinical</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Phase I Human
Clinical Trials &ndash; </I>Folate Alpha Breast and Ovarian Cancer &ndash; Mayo Clinic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Folate Receptor Alpha is expressed in over
80% of triple negative breast cancers and in addition, over 90% of ovarian cancers, for which the only treatment options are surgery,
radiation and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively
short for these types of cancer and survival prognosis is extremely poor after recurrence. In the United States alone, there are
approximately 30,000 ovarian cancer patients and 40,000 triple negative breast cancer patients newly diagnosed every year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>TPIV 200 Folate Receptor Alpha</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A 24 patient Phase I clinical trial has
been completed. The vaccine is well tolerated and safe and 20 out of 21 evaluable patients showed positive immune responses providing
a strong rationale rational for progressing to phase II trials. GMP manufacturing for Phase II trials is progressing well towards
a commercial formulation and final analyses of clinical plans are near completion. On July 27, 2015,<FONT STYLE="color: #28292A">
</FONT>TapImmune exercised its option agreement with Mayo Clinic with the signing of a worldwide exclusive license agreement to
commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. As part of this Agreement, the
IND for the folate receptor alpha Phase I trial was transferred from Mayo to TapImmune for amendment for the Company&rsquo;s Phase
II Clinical Trials<B><I> </I></B>on our lead product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 15, 2015, we announced that
our collaborators at the Mayo Clinic had been awarded a grant of $13.3 million from the U.S. Department of Defense. This grant,
commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine
in patients with Triple Negative Breast Cancer.<FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #28292A">
</FONT>TapImmune will work closely with Mayo Clinic on this clinical trial by providing clinical and manufacturing expertise as
well as providing GMP vaccine formulations. These vaccine formulations are being developed for multiple Phase II clinical programs
in triple negative breast and ovarian cancer in combination with other immunotherapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2015, we announced that
we received Orphan Drug Designation from the U.S. Food &amp; Drug Administration&rsquo;s Office of Orphan Products Development
(OOPD) for our cancer vaccine TPIV 200 in the treatment of ovarian cancer. The TPIV 200 ovarian cancer clinical program will now
receive benefits including tax credits on clinical research and 7-year market exclusivity upon receiving marketing approval. TPIV
200 is a multi-epitope peptide vaccine that targets Folate Receptor Alpha which is overexpressed in multiple cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2016 we announced that the
U.S. Food &amp; Drug Administration (FDA) has designated the investigation of multiple-epitope Folate Receptor Alpha Peptide Vaccine
(TPIV 200) with GM-CSF adjuvant for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer who achieved
stable disease or partial response following completion of standard of care chemotherapy, as a Fast Track Development Program.
A Phase 2 study in this indication is being readied for initiation by the end of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently enrolling a Company sponsored
triple negative breast cancer study at 8 clinical sites nation-wide. The study will enroll 80 patients. It is open-label and designed
to look at dosing regimens, immune responses and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also announced the start of
an ovarian cancer study sponsored by Memorial Sloan Kettering Cancer Center in New York City in collaboration with Astra Zeneca
Pharmaceuticals. This study is currently enrolling platinum resistant ovarian cancer patients and is designed to look at the effects
of combination therapy with Astra Zeneca&rsquo;s checkpoint inhibitor durvalamab. The study will enroll 40 patients and is open
label. Although we have no business relationship with Astra Zeneca, we are paying for half of the clinical study plus providing
our TPIV 200 for the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Phase I Human
Clinical Trials &ndash; HER2/neu+ Breast Cancer &ndash; Mayo Clinic</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patient dosing has been completed. Final
safety analysis on all the patients treated is complete and shown to be safe. In addition, 19 out of 20 evaluable patients showed
robust T-cell immune responses to the antigens in the vaccine composition providing a solid case for advancement to Phase II in
2015. An additional secondary endpoint incorporated into this Phase I Trial will be a two year follow on recording time to disease
recurrence in the participating breast cancer patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Phase I(b)/II studies, we plan to add
a Class I peptide, licensed from the Mayo Clinic (April 16, 2012), to the four Class II peptides. Management believes that the
combination of Class I and Class II HER2/neu antigens, gives us the leading HER2/neu vaccine platform. As the folate receptor alpha
vaccine is our lead product our plans are now initiating formulation studies to progress the HER2/neu vaccine towards a Phase II
Clinical Trial in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Products and Technology-Preclinical
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Polystart</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We converted the previously filed U.S.
Provisional Patent Application on Polystart into a full Patent Application, and in February 2016 we received a Notice of Allowance
from the U.S. Patent and Trademark Office (USPTO) for a patent application entitled, &ldquo;A chimeric nucleic acid molecule with
non-AUG initiation sequences.&rdquo; The term of this patent extends to March 17, 2034. Additional patent filings are in progress.
We plan to develop PolyStart as both a stand-alone therapy and as a &lsquo;boost strategy&rsquo; to be used synergistically with
our peptide-based vaccines for breast and ovarian cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Current
State of the Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are a clinical-stage
immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for
the treatment of cancer. We now plan to conduct multiple Phase II clinical trials on our vaccines. The largest of these studies
in triple-negative breast cancer is totally funded by a $13.3 million grant from the U.S. Department of Defense to our collaborators
at the Mayo Clinic in Jacksonville, Florida. A Company-sponsored trial in triple negative breast cancer started during the second
quarter of 2016 with recruitment at multiple sites and treatment of first patients. We believe that our development pipeline is
strong and provides us the opportunity to continue to expand on collaborations with leading institutions and corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe, the
strength of our science and development approaches is becoming more widely appreciated, particularly as our clinical program has
now generated positive interim data on both clinical programs in Breast and Ovarian Cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We continue to
be focused on our entry into Phase II Triple Negative Cancer Trials including application for Fast Track &amp; Orphan Drug Status
as well as planning for Phase II HER2/neu Breast Cancer Trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We expect to continue
to prosecute our PolyStart patent filings and develop new constructs to facilitate collaborative efforts in our current clinical
indications and those where others have already indicated interest in combination therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe that
these fundamental programs and corporate activities have positioned TapImmune to capitalize on the acceptance of immunotherapy
as a leading therapeutic strategy in cancer and infectious disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>TapImmune&rsquo;s
Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Clinical
Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="pg18img1_10q.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have a pipeline
of potential immunotherapies under development. Phase I clinical programs on HER2/neu for breast and ovarian cancer have been completed
and strong immune responses in over 90% of patients treated has provided the rationale and catalyst to advance these programs to
Phase II clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition to
the exciting clinical developments, our peptide vaccine technology may be coupled with our recently developed in-house Polystart
nucleic acid-based technology designed to make vaccines significantly more effective by producing four times the required peptides
for the immune systems to recognize and act on. Our nucleic acid-based systems can also incorporate &ldquo;TAP&rdquo; which stands
for&nbsp;Transporter associated with&nbsp;Antigen&nbsp;Presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A key component
to success is having a comprehensive patent strategy that continually updates and extends patent coverage for key products. It
is highly unlikely that early patents will extend through ultimate product marketing, so extending patent life is an important
strategy for ensuring product protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have three
active patent families that we are supporting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">1. Filed patents
on PolyStart expression vector (owned by TapImmune and filed in 2014: this IP covers the use with TAP). The Company announced the
allowance of this patent in February 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">2. Filed patents
on HER2/neu Class II and Class I antigens: exclusive license from Mayo Foundation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">3. Filed patents
on Folate Receptor Alpha antigens: exclusive license from Mayo Foundation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">While the pathway
to successful product development takes time, we believe we have put in place significant for success. The strength of our product
pipeline and access to leading scientists and institutions gives us a unique opportunity to make a major contribution to global
health care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">With respect to
the broader market, a major driver and positive influence on our activities has been the emergence and general acceptance of the
potential of a new generation of immunotherapies that promise to change the standard of care for cancer. The immunotherapy sector
has been greatly stimulated by the approval of Provenge&reg; for prostate cancer and Yervoy&trade; for metastatic melanoma, progression
of the areas of checkpoint inhibitors and adoptive T-cell therapy and multiple approaches reaching Phase II and Phase III status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that through our combination
of technologies, we are well positioned to be a leading player in this emerging market. It is important to note that many of the
late stage immunotherapies currently in development do not represent competition to our programs, but instead offer synergistic
opportunities to partner our antigen based immunotherapeutics, and Polystart expression system. Thus, the use of naturally processed
T-cell antigens discovered using samples derived from cancer patients plus our Polystart expression technology to improve antigen
presentation to T-cells could not only produce an effective cancer vaccine in its own right but also to enhance the efficacy of
other immunotherapy approaches such as CAR-T and PD1 inhibitors for example.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments and Company Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Research Programs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Her2neu
License Agreement</I></B><I> </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 7, 2016
we announced that we exercised our option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary
HER2neu vaccine technology. The license gives us the right to develop and commercialize the technology in any cancer indication
in which the Her2neu antigen is overexpressed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Phase II
Trials Started</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 26, 2016
we announced plans to participate in a Phase 2 trial of our cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine
(FR&alpha;), in combination with durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer.
The study started with the enrollment and treatment of patients in the second quarter of 2016 at Memorial Sloan Kettering Cancer
Center in New York and is being led by Jason Konner, M.D. as Principal Investigator. On June 21, 2016, we announced the treatment
of the first patient in a company-sponsored Phase II trial in triple negative breast cancer as part of a multi-center study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Manufacturing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 7, 2016,
we announced that we have successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing,
and the release of TPIV 200, our multi-epitope folate receptor peptide vaccine for breast and ovarian cancer. The manufactured
product contains five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of
granulocyte-macrophage colony-stimulating factor (GM-CSF). TPIV 200 doses are now available for the upcoming Phase II clinical
trials in both triple negative breast cancer and ovarian cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Recent Developments</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enrolling Patients: Phase 2 TPIV
200 Trial in Triple Negative Breast Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have opened 8 clinical sites and begun
treating patients in a Phase 2 trial of our Folate Receptor Alpha cancer vaccine, TPIV 200, in the treatment of triple negative
breast cancer, one of the most difficult to treat cancers representing a clear unmet medical need. The open-label, 80 patient clinical
trial is designed to evaluate dosing regimens, adjuvants, efficacy, and immune responses in women with triple negative breast cancer.
Key data from the trial is expected to be included in a future New Drug Application submission to the FDA for marketing clearance.
This trial is sponsored and conducted by TapImmune.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enrolling Patients: Phase 2 Trial
at Memorial Sloan Kettering of TPIV 200 in Ovarian Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Phase 2 study of TPIV 200 in ovarian
cancer patients who are not responsive to platinum, a commonly used chemotherapy for ovarian cancer, sponsored by Memorial Sloan
Kettering Cancer Center, and in collaboration with AstraZeneca and TapImmune, has begun enrollment for a 40 patient study. The
open-label study is designed to evaluate a combination therapy which includes our TPIV 200 T-cell vaccine and AstraZeneca&rsquo;s
checkpoint inhibitor, durvalumab. Because they are unresponsive to platinum, these patients have no real options left. If the combination
therapy proves effective, we believe it would address a critical unmet need. TPIV 200 has received Orphan Drug designation for
use in the treatment of ovarian cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enrollment to Commence in Q4 2016:
Phase 2 Mayo Clinic-U.S. DOD Trial of TPIV 200 in Triple Negative Breast Cancer</I></B><I> </I>We anticipate this Phase 2 study
of TPIV 200 in the treatment of triple negative breast cancer, conducted by the Mayo Clinic and sponsored by the U.S. Department
of Defense (DOD), will begin to enroll patients in the fourth quarter of this year. The anticipated 280 patient study will be led
by Dr. Keith Knutson of the Mayo Clinic in Jacksonville, Florida. Dr. Knutson is the inventor of the technology and an advisor
to TapImmune. While TapImmune is supplying doses of TPIV 200 for the trial, the remaining costs associated with conducting this
study will be funded by a $13.3 million grant made by the DOD to the Mayo Clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical Sites to Open in Q4 2016:
Phase 2 TPIV 200 Trial in Platinum-Sensitive Ovarian Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By the end of 2016, we expect to have at
least one clinical site open in a Phase 2 trial of TPIV 200 in 80 ovarian cancer patients who are responsive to platinum. We have
received the FDA&rsquo;s Fast Track designation to develop TPIV 200 as a maintenance therapy in combination with platinum, in platinum
responsive ovarian cancer. This multi-center, double-blind efficacy study is sponsored and conducted by TapImmune.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Open IND with FDA for TPIV 110 in
Q4 2016 or in Q1 2017: Phase 2 Protocol Now in Preparation</I></B><I> </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have reformulated our second cancer
vaccine product, TPIV 110, following very strong safety and immune responses from a Phase 1 Mayo Clinic study. TPIV 110 targets
Her2/neu, which makes it applicable to breast, ovarian and colorectal cancer. The reformulated product adds a fifth antigen which
should produce an even more robust immune response activating both CD4+ and CD8+ T-cells. We have requested a pre-Investigational
New Drug (IND) meeting with the FDA and submitted questions to the FDA related to opening the IND. A response from the FDA is expected
in September and we anticipate having an open IND by year-end pending comments from FDA. The protocol for a Phase 2 trial of TPIV
110 in the treatment of Her2/neu positive breast cancer patients has been designed and is now being reviewed by our Scientific
Advisory Board and collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>TPIV Products are Off-the-Shelf,
Commercially Viable, with Excellent Potential Margins</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are continuously working on improving
our product formulation and supply. We believe TPIV 200 and TPIV 110 are both very stable, off-the-shelf, lyophilized products
that only require reconstitution at the clinical site before injection. We believe the investments we have made in the formulation
work we have performed will result in a commercially viable product with excellent potential profit margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Robust Product Data &amp; Independent
Vetting Key to High-Value Collaborations</I></B><I> </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Phase 1 data produced for
both TPIV 200 and TPIV 100 in collaboration with the Mayo Clinic are the driving force behind the high-value collaborations we
have been able to maintain and establish with organizations including Mayo Clinic, AstraZeneca, Sloan Kettering, and the U.S. Department
of Defense. As we move forward into advancing the Phase 2 studies, some of which are represent collaboration with prestigious third
party organizations, we believe this represents further independent vetting of potential of our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2016, at the opening
of trading, we effected a one-for-twelve reverse split of our common shares. The common shares began trading on a split-adjusted
basis on September 16, 2016. The reverse stock split was effected in connection with the Company&rsquo;s intent to apply to list
the common stock on the NASDAQ Capital Market. On November 2, 2016, we received notification that we were approved for listing
on The Nasdaq Capital Market. Our common stock is expected to begin trading on The Nasdaq Capital Market at the opening of trading
on Tuesday, November 8, 2016 under the ticker symbol, TPIV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our historical financial results have been
adjusted to reflect a reduction in the number of shares of our outstanding common stock from 62,890,763 shares to 5,240,897 shares
at September 30, 2015 and from 70,550,763 shares to 5,879,230 shares at December 31, 2015. In addition, effective upon the reverse
stock split, the number of authorized shares of our common stock was reduced from 500 million shares to 41,666,667 shares. All
fractional shares resulting from the reverse stock split were rounded up to the nearest whole share. All share data herein has
been retroactively adjusted for the reverse stock split. The par value was not adjusted as a result of the one for twelve reverse
stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>August 2016
Private Placement Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2016 and August 25, 2016,
the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the
Company&rsquo;s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common
stock for $6.00. The Company issued and sold an aggregate of 653,166 units at a purchase price per unit of $4.80 for an aggregate
of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company issued five-year
warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the registration rights agreements
entered into in connection with the private placements, the Company is required to file a registration statement with the Securities
and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of
common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise
of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the
August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared
effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the registration rights
agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages.
The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase
price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with applicable U.S. generally
accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration
under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it
be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be
required to record would be approximately $29,000 per month for each month it fails or is estimated to fail to meet the above criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the August 10, 2016 and August 26,2016
private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required to
remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>August 2016 Warrant Exercises</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2016, holders of an aggregate
of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants, each providing for the purchase of one share of our common
stock for $6.00 per share, exercised their warrants for an aggregate exercise price of $6,000,000.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>August 2016 Warrant Amendments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simultaneous with the exercise of the warrants,
we and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants,
Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants (the &ldquo;Outstanding Series Warrants&rdquo;)
entered into Warrant Amendment Agreements (the &ldquo;Amendment Agreement&rdquo;), in which they agreed to amend the terms of the
Outstanding Series Warrants to remove provisions from the Outstanding Series Warrants that had previously caused them to be classified
as a derivative liability as opposed to equity on our balance sheet.&nbsp;In consideration for such amendment and the exercise
of the Series C Warrants and Series C-1 Warrants, we issued an aggregate of 750,000 additional shares of common stock to such warrant
holders and new five-year warrants to purchase 1 million shares of our common stock at an exercise price of $7.20 per share (the
&ldquo;Series F and F-1Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reflects the status
of the outstanding warrants from the January 2015, March 2015, and August 2016 private placement financings (including placement
agent warrants) following the Amendment Agreement and private placement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Series</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Outstanding Warrants</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Exercise Price</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Expiration</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: left; vertical-align: top">A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">214,433</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">01/13/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424,433</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>01/13/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">610,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">E</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">616,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">A-1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">418,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>03/09/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">C-1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>01/13/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">D-1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Between 08/19/2020 and 09/09/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">E-1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">418,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>06/16/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">F</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">583,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>8/11/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">F-1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>8/11/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none; text-align: left; vertical-align: top">PIPE Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>8/11/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Broker Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>8/11/2021</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Addition
of Executive Officers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July&nbsp;18,
2016 we announced that Dr.&nbsp;John Bonfiglio, a consultant and a member of our Board of Directors, was appointed as our President
and Chief Operating Officer and entered into an employment agreement with us. Concurrent with such appointment we amended the employment
agreement of Dr. Wilson for Dr. Wilson to relinquish the office of President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 25,
2016 we announced that Michael J. Loiacono, a consultant, was appointed as our Chief Financial Officer, Chief Accounting Officer,
Secretary and Treasurer and entered into an employment agreement with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Critical Accounting Policies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated financial statements
are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported
amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances
are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates,
requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial
statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report
on Form 10-K for the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In this discussion
of the Company&rsquo;s results of operations and financial condition, amounts, other than per-share amounts, have been rounded
to the nearest thousand dollars.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Three Months Ended September 30, 2016 Compared to Three
Months Ended September 30, 2015</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded a net loss of $2,103,000 or
($0.29) basic and diluted per share during the three months ended September 30, 2016 compared to a net income of $28,503,000 or
$7.04 basic and $4.23 diluted per share during the three months ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating costs increased to $2,722,000
during the three months ended September 30, 2016 compared to $1,738,000 in the prior period. Significant changes in operating expenses
are outlined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Research and development costs during the three months ended September 30, 2016 were $1,109,000
compared to $969,000 during the prior period. The increase was primarily due to the Company expensing the Mayo Foundation license
fee payments in the current period and higher expenses relating to research.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">General and administrative expenses increased to $1,612,000 during the three months ended September
30, 2016 from $769,000 during the prior period. This was due to generally increased expenses relating to consulting, general and
administrative and professional fees during the three months ended September 30, 2016 due to increased activity in operations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The changes in fair value of derivative liabilities for the three months ended September 30, 2016
was $684,000 as compared to $30,266,000 for the three months ended September 30, 2015. The variance is due to the revaluation of
the Series A and A-1, Series C and C-1, Series D and D-1 and Series E and E-1 warrants issued by us in January and March 2015.
We revalue the derivative liabilities at each balance sheet date to fair value. The fair value is determined using Black-Scholes
valuation model using various assumptions. The most significant changes in the assumptions was the difference in the strike price
used at September 30, 2016 of $6.69 compared to $7.40 at September 30, 2015, the exercise of warrants with derivative liabilities
and the August 2016 amendments to certain of the warrants to remove the clause that caused the warrants to be classified as derivative
liabilities. Due to these significant changes, the fair value of the derivative liabilities decreased by $684,000 with a corresponding
gain in the condensed consolidated statement of operations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the three-month period ended September 30, 2016 the Company incurred $65,000 loss on debt
settlement agreements relating to an outstanding agreement from a previous year. This compares to $25,000 loss on debt settlement
agreements for the three months ended September 30, 2015.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Nine months ended September 30, 2016 Compared to Nine
months ended September 30, 2015</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded a net loss of $879,000 or ($0.14)
basic and ($0.54) diluted per share during the nine months ended September 30, 2016 compared to a net loss of $32,414,000 or ($10.61)
basic and diluted per share for the nine months ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating costs increased to $6,901,000
during the nine months ended September 30, 2016 compared to $3,904,000 in the prior period. Significant changes in operating expenses
are outlined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Research and development costs during the nine months ended September 30, 2016 were $3,343,000
compared to $2,324,000 during the prior period. This was due to the Company exercising its option to acquire Mayo Clinic technology
as part of an agreement entered into in March 2014 and increased in-house research activity in the current period.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">General and administrative expenses increased to $3,558,000 during the nine months ended September
30, 2016 from $1,580,000 during the prior period. This was due to generally increased expenses relating to consulting, general
and administrative and professional fees during the nine months ended September 30, 2016 as the Company&rsquo;s operating activities
increased substantially.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The changes in fair value of derivative liabilities for the nine months ended September 30, 2016
was $5,925,000 as compared to ($28,486,000) for the nine months ended September 30, 2015. The variance in the current period is
due to the revaluation of the Series A and A-1, Series C and C-1, Series D and D-1 and Series E and E-1 warrants issued by us in
January and March 2015. We revalue the derivative liabilities at each balance sheet date to fair value. The most significant changes
in the assumptions was the difference in the strike price used at September 30, 2016 of $6.69 compared to $7.40 at September 30,
2015, the exercise of warrants with derivative liabilities and the August 2016 amendments to certain of the warrants to remove
the clause that caused the warrants to be classified as derivative liabilities. Due to these significant changes, the fair value
of the derivative liabilities decreased by $5,925,000 with a corresponding gain in the condensed consolidated statement of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the nine months ended September 30, 2016, the Company received $231,000 of a grant awarded
to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical
supplies purchased by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the nine-month period ended September 30, 2016 the Company incurred $135,000 loss on debt settlement agreements relating
to an outstanding debt agreement from previous years. This compares to $25,000 loss on debt settlement agreements for the nine
months ended September 30, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity and Capital Resources </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not generated any revenues since
inception, we have financed our operations primarily through public and private offerings of our stock and debt including warrants
and the exercise thereof. The following table sets forth our cash and working capital as of September 30, 2016 and December 31,
2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;September
30, 2016</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
31, 2015 </B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Cash reserves</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">9,587,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">6,577,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Working capital (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,494,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(21,360,000</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash Flows </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes our cash flows for the nine months
ended September 30, 2016 and 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by (used in):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; text-indent: -12pt; padding-left: 0.5in">Operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(4,756,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(3,492,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,766,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,438,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 60pt; padding-bottom: 2.5pt">Net increase in cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">3,010,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5,945,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Net Cash
Used in Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during
the nine months ended September 30, 2016 was $4,756,000 compared to $3,492,000 during the prior period. We had no revenues during
the current or prior periods. Operating expenditures, excluding non-cash interest and stock-based charges during the current period
primarily consisted of consulting and management fees, office and general expenditures, and professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Cash Provided by Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities
during the nine months ended September 30, 2016 was $7,766,000 compared to net cash provided by financing activities of $9,438,000
during the prior period. The financing consisted of proceeds from private placements and warrant exercises in the current period
as was in the prior period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our current available
funding has come from financings that we conducted in January and March of 2015 and from the exercise of warrants issued in connection
with our January and March, 2015 financings as well as our recent August 2016 private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>January
2015 Financing </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In January, 2015,
we entered into a Securities Purchase Agreement with certain investors for the sale of 610,000 units at a purchase price of $2.40
per unit, for a total purchase price of approximately $1,250,000, net of finders&rsquo; fee and offering expenses of approximately
$214,000. Each unit consisting of (i) one share of the Company&rsquo;s Common Stock, (ii) one Series A warrant to purchase one
share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one
share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase
one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the &ldquo;January 2015
Warrants&rdquo;). Series A warrants were exercisable at $18.00 per share, with a five-year term. Series B warrants were exercisable
at $4.80 per share, with a six-month term. Series C warrants were exercisable at $12.00 per share, with a five-year term. Series
D warrants were exercisable at $9.00 per share only if and to the extent that the Series B warrants are exercised, with a five-year
term from the date that the Series B warrants are exercised. Series E warrants were exercisable at $15.00 per share, only if and
to the extent that the Series C warrants are exercised, with a five-year term from the date that the Series C warrants are exercised.
Pursuant to a placement agent agreement, we agreed to issue warrants to purchase 30,500 common shares with substantially the same
terms as the January 2015 Warrants. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>March 2015
Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In March, 2015,
we entered into a Securities Purchase Agreement with certain accredited investors for the sale of 416,667 units at a purchase price
of $2.40 per unit, for a total purchase price of approximately $950,000, net of finders&rsquo; fee and offering expenses of approximately
$50,000. Each unit consisting of (i) one share of the Company&rsquo;s Common Stock, (ii) one Series A-1 warrant to purchase one
share of common stock, (iii) one Series B-1 warrant to purchase one share of common stock (iv) one Series C-1 warrant to purchase
one share of common stock, (v) one Series D-1 warrant to purchase one share of common stock, and (vi) one Series E-1 warrant to
purchase one share of common stock (the Series A-1, B-1, C-1, D-1 and E-1 warrants are hereby&nbsp;collectively referred to as
the &ldquo;March 2015 Warrants&rdquo;). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.
&nbsp;Pursuant to a placement agent agreement, we agreed to issue warrants to purchase 10,417 common shares with substantially
the same terms as the March 2015 Warrants. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Restructuring
of January and March 2015 Financings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In May 2015, we
entered into a restructuring agreement with the investors of the January 2015 and March 2015 financings, where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The exercise price of the Series A and Series A-1 warrants was changed from $18.00 per share to
$1.20 per share,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The exercise price of Series B and Series B-1 warrants was changed from $4.80 per share to $2.40
per share,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Each warrant of Series B and Series B-1 existing prior to the restructuring agreement was replaced
with two warrants of such series,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The exercise price of the Series C and Series C-1 warrants was changed from $12.00 per share to
$6.00 per share, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Each warrant of Series C and Series C-1 existing prior to the restructuring agreement was replaced
with two warrants of such series.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a result of
the restructuring agreement, we issued an additional 1,026,667 Series B and B-1 warrants and 1,026,667 Series C and C-1 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>2016 Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>August 2016
Private Placement Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2016 and August 25, 2016,
the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the
Company&rsquo;s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common
stock for $6.00. The Company issued and sold an aggregate of 653,166 units at a purchase price per unit of $4.80 for an aggregate
of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company issued five-year
warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the registration rights agreements
entered into in connection with the private placements, the Company is required to file a registration statement with the Securities
and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of
common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise
of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the
August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared
effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the registration rights
agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages.
The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase
price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with applicable U.S. generally
accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration
under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it
be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be
required to record would be approximately $29,000 per month for each month it fails or is estimated to fail to meet the above criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the August 10, 2016 and August 26,2016
private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required to
remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrant Exercises</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Between June 16,
2015 and December 9, 2015, 3,090,000 shares were issued upon exercise of certain warrants we issued in connection with our 2015
financings, providing $9.22 million in proceeds. In August 2016, holders of an aggregate of 583,333 outstanding Series C Warrants
and 416,667 Series C-1 Warrants, each providing for the purchase of one share of our common stock for $6.00 per share, exercised
their warrants for an aggregate exercise price of $6,000,000.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Future Capital Requirements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our capital requirements through 2017 will
depend on numerous factors, including the success of our research and development, the resources we devote to develop and support
our technologies and our success in pursuing strategic licensing and funded product development relationships with external partners.
Subject to our ability to raise additional capital including through possible joint ventures and/or partnerships, we expect to
incur substantial expenditures to further develop our technologies including continued increases in costs related to research,
nonclinical testing and clinical studies, as well as costs associated with our capital raising efforts and being a public company.
We intend to spend approximately $7,500,000 over the next twelve months in carrying out our plan of operations. We will require
substantial funds to conduct research and development and nonclinical and Phase II clinical testing of our licensed, patented technologies
and to develop sublicensing relationships for the Phase II and III clinical testing. Our plans include seeking both equity and
debt financing, alliances or other partnership agreements with entities interested in our technologies, or other business transactions
that would generate sufficient resources to ensure continuation of our operations and research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to continue to seek additional
funding for our operations. Any such required additional capital may not be available on reasonable terms, if at all. If we were
unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned
clinical testing and research and development activities, which could harm our business. The sale of additional equity or debt
securities may result in additional dilution to our shareholders. If we raise additional funds through the issuance of debt securities
or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would
restrict our operations. We also will require additional capital beyond our currently forecasted amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the numerous risks and uncertainties
associated with research, development and commercialization of our product candidates, we are unable to estimate the exact amounts
of our working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number and characteristics of the product candidates we pursue;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the scope, progress, results and costs of researching and developing our product candidates, and
conducting nonclinical and clinical trials including the research and development expenditures we expect to make in connection
with our license agreements with Mayo Foundation;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to maintain current research and development licensing agreements and to establish
new strategic partnerships, licensing or other arrangements and the financial terms of such agreements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to achieve our milestones under our licensing arrangements and the payment obligations
we may have;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent
claims, including litigation costs and the outcome of such litigation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing, receipt and amount of sales of, or royalties on, our future products, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based our estimates on assumptions
that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential
sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek
to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not
have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we
need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other
securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able
to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit
our operations and our business, financial condition and results of operations would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various conditions outside of our control
may detract from our ability to raise additional capital needed to execute our plan of operations, including overall market conditions
in the international and local economies. We recognize that the United States economy has suffered through a period of uncertainty
during which the capital markets have been impacted, and that there is no certainty that these levels will stabilize or reverse
despite the optics of an improving economy. Any of these factors could have a material impact upon our ability to raise financing
and, as a result, upon our short-term or long-term liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Going Concern</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no sources of revenue to provide
incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our planned business activities
is dependent upon our successful efforts to raise additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While these factors raise substantial doubt
regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going
concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of
business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts
and classification of liabilities that might be necessary should we be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not entered into any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes of
financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material
to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_009"></A>Item 3.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Quantitative and Qualitative Disclosures About Market Risk</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a smaller reporting company as defined
by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_010"></A>Item 4.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Controls and Procedures</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>(a)</B></TD><TD STYLE="text-align: justify"><B>Evaluation of Disclosure Controls and Procedures</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation
of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and
procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered
by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that
information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to
management, including our Chief Executive Officer and  Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded
that, as of the end of the period covered by this report, our disclosure controls and procedures are not effective in recording,
processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file
or submit under the Exchange Act. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be noted that any system of controls is based in part
upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no
assurance that any design will succeed in achieving its stated goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>(b)</B></TD><TD STYLE="text-align: justify"><B>Changes in Internal Control Over Financial Reporting</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes in our internal
control over financial reporting during the nine months ended September 30, 2016 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="TAP_011"></A><B>PART II &ndash; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_012"></A>Item 1.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Legal Proceedings</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management is not aware of any material
legal proceedings and there are no pending material procedures that would affect the property of the Company. Management is not
aware of any legal proceedings contemplated by any government authority or any other party involving the Company. As of the date
of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an
adverse interest to us in any legal proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_013"></A>Item 1A.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Risk Factors</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For risk factors, see Item 1.A.-&ldquo;Risk
Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_014"></A>Item 2.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Unregistered Sales of Equity Securities and Use of Proceeds</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">(a)</TD>
    <TD STYLE="text-align: justify">We issued the following unrestricted securities during the period covered by this report to the named individual pursuant to exemptions under the Securities Act of 1933 including Section&nbsp;4(2): </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On July
18, 2016 the Company issued 20,833 shares to Dr. John Bonfiglio pursuant to the employment agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On August
10, 2016, the Company issued and sold 653,166 shares of stock as part of a private placement with certain accredited investors.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On August
11, 2016, the Company issued 1,000,000 shares of stock in relation to the exercising of 583,333 outstanding Series C Warrants and
416,667 Series C-1 Warrants. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On August
11, 2016, the Company issued 750,000 shares of stock to warrant holders as an inducement to amend certain warrant agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><A NAME="TAP_015"></A>Item 3.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Defaults Upon Senior Securities</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_016"></A>Item 4.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Mine Safety Disclosure</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_017"></A>Item 5.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Other Information</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; border-bottom: Black 1pt solid; font-weight: bold"><A NAME="TAP_018"></A>Item 6.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Exhibits</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following exhibits are included with
this Quarterly Report on Form 10-Q:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="5" NOWRAP STYLE="padding-left: 0.1in; text-align: center"><B>Incorporated by Reference</B></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0.1in"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>number</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 44%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit description</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Form</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>File&nbsp;no.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Filing</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>date</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 8%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Filed</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>herewith</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Articles of Incorporation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">31.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">31.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Certification of Chief Financial Officer and Chief Accounting Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>X</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">32.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>X</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">32.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Certification of Chief Financial Officer and Chief Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>X</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Exhibit 101</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">101.INS </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">XBRL Instance Document</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">101.SCH </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">XBRL Taxonomy Extension Schema
Document</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">101.CAL </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">XBRL Taxonomy Extension Calculation
Linkbase Document</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">101.DEF </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">XBRL Taxonomy Extension Definition
Linkbase Document</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">101.LAB </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">XBRL Taxonomy Extension Label
Linkbase Document</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">101.PRE </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">XBRL Taxonomy Extension Presentation
Linkbase Document</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>X</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="TAP_019"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the requirements of
the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TAPIMMUNE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid"><I>/s/ Glynn Wilson</I></TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>Glynn Wilson</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Chairman, Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Date: November 4, 2016</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed in the office of the </FONT><BR>
<FONT STYLE="font-size: 10pt">Secretary of State of the </FONT><BR>
<FONT STYLE="font-size: 10pt">STATE OF NEVADA</FONT></TD>
    <TD STYLE="width: 75%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 22, 1991</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLES OF INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WARD&rsquo;S FUTURA ATOMOTIVE, LTD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KNOW ALL MEN BY THESE PRESENTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, the undersigned,
natural persons of the age of 21 year, or more, acting as incorporators of a corporation under the Nevada Business Corporation
Act, adopt the following Articles of Incorporation for such corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE I - NAME</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the Corporation
shall be WARD'S FUTURA ATOMOTIVE, LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE II - DURATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The period of its duration
shall be perpetual unless dissolved or terminated according to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE III &ndash; CORPORATE PURPOSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general purposes
and objects for which the corporation is organized are to engage primarily in any type of manufacturing of automobiles, and/or
marketing of automobiles or, automotive related products both retail and wholesale. Realstate unimproved or improved, land development,
and/or investment in real property or real estate related endeavors. To engage in any business, investment or other pursuit or
activity, whether retail or wholesale, whether commercial or industrial; and to perform any and all other lawful acts or purposes
as are or may be granted to corporate entitles under the laws of the State of Nevada and by any other state or foreign country.
The corporation may conduct its business anywhere within the States of the United States of America or in any foreign country,
without in any way limiting the foregoing powers. It is hereby provided that the corporation shall have the power to do any and
all acts and things that may be reasonably necessary or appropriate to accomplish any of the foregoing purposes for which the corporation
is formed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IV - SHARES OF STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate number
of shares which the corporation shall have authority to issue is 50,000,000 shares of common stock at par value of $0.001 per share,
or a total capitalization of $50,000.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There shall be no cumulative
voting, and all pre-emptive rights are denied. Each share shall entitle the holder thereof to one vote at all meetings of the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders shall
not be liable to the corporation or its creditors for any debts or obligations of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE V - STOCK RESTRICTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All shares of stock
in the company are assignable and any stockholder may sell, assign and transfer his shares, and certificates of stock at pleasure
except that no such transfer, sale or assignment shall be valid unless and until it shall have been entered upon the books of the
company and the old certificate or certificates shall have been surrendered for cancellation to the Secretary and a new certificate
or certificates issued in lieu of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VI COMMENCING BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation will
not commence business until consideration of the value of at least One Thousand Dollars (1,000.00) has been received for the issuance
of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VII - REGISTERED AGENT AND OFFICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name and post office
address of its initial registered agent is Donald C. Bradley. 5312 Ithaca, Las Vegas, NV, 89122</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VIII - DIRECTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That the number of
directors of this corporation, their qualifications, terms of office and the time and manner of their election, removal and resignation
shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The number of directors shall
not be less than two (2) nor more than seven (9), the exact number within such limits to be determined in the manner prescribed
by the by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors shall be
elected at the annual meeting of the stockholders of this corporation and shall serve for one (1) year and until their successors
shall have been duly elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A majority of the entire
number of directors, but not less than (2), shall be necessary to form a quorum of the board of directors, authorized to transact
the business and exercise the corporate powers of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such officers shall
consist of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One
or more Vice Presidents as shall be provided by the by-laws or the board of directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
Secretary: and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
Treasurer - may be held by officers who concurrently hold another office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such officers shall
be elected annually by the board of directors and shall serve for one (1) year and until their successors shall have been duly
elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any officer may be
removed by vote of a majority of the board of directors or in such other manner as may be prescribed in the by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That the following
named person, parties hereto, the directors and officers of this corporation from the date hereof and until their successors shall
have been elected and qualified:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">PRESIDENT &amp; DIRECTOR:</TD>
    <TD STYLE="width: 50%; text-align: justify">DONALD C. BRADLEY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">5312 ITHACA</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">LAS VEGAS, NV 09122</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">VICE PRESIDENT &amp; DIRECTOR:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">SECRETARY/TREASURER &amp; DIRECTOR:</TD>
    <TD STYLE="text-align: justify">SHIRLENE BRADLEY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">5312 ITHACA</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">LAS VEGAS, NV 89122</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE X - SHAREHOLDER LIABILITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That the private property
of the stockholders of this corporation shall not be liable for the debts or obligations of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE XI - INCORPORATORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name and address
of each incorporator is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DONALD C. BRADLEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5312 ITHACA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LAS VEGAS, NV 89122</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SHIRLENE BRADLEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5312 ITHACA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LAS VEGAS, NV 89122</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE XII - 1244 STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares of stock of
this corporation authorized and issued pursuant to these Articles of Incorporation within two (2) years from the date of incorporation
are, for the purpose of the Internal Revenue Code, authorized and issued in. compliance with and as prescribed by Section 1244
of the Internal Revenue Code of 1954, as amended shall be known as &quot;Section 1244 Stock&quot;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE XIII &ndash; DIRECTORS&rsquo; OF
OFFICERS&rsquo; CONTRACTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No contract or other
transaction between this corporation and one or more of its directors or any other corporation. firm, association or entity in
which one or more of its directors are directors or officers are financially interested shall be either void or voidable because
of such relationship or interest, or because such director or directors are present at the meeting of the board of directors or
a committee thereof, which authorizes, approves or ratifies such contracts or transaction, or, because his or their votes are counted
for such purpose, if: (a) the fact of such relationship or interest is disclosed or known to the board of directors or committee
which authorizes, approves or ratifies the contract or transaction by vote or consent sufficient for the purpose without counting
the votes or consents of such interested director: or (b) the fact of such relationship or interest is disclosed or known to the
shareholders entitled to vote and they authorize, approve or ratify such contract or transaction by vote or written consent: or,
(c) the contract or transaction is fair and reasonable to the corporation. Common or interested directors may be counted in determining
the presence of a quorum at a meeting of the board of directors or committee thereof which authorizes, approves or ratifies such
contract or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">INCORPORATORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: justify">STATE OF NEVADA</TD>
    <TD STYLE="width: 75%; text-align: justify">)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">COUNTY OF CLARK</TD>
    <TD STYLE="text-align: justify">)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 21, 1991,
personally appeared before me, Donald C. Bradley and Shirlene Bradley, who being duly sworn by me first, declared that he had read
the foregoing Articles of Incorporation, that he had signed the foregoing document as an incorporator and that the statements contained
therein are true.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
I have hereunto set my hand and seal this day of <U>October</U>, 1991</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify">/s/ Donald C. Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Donald C. Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Shirlene Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Shirlene Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ O Chase</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">NOTARY PUBLIC</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">My Commission Expires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border-bottom: Black 1pt solid; text-align: center">2-4-95</TD>
    <TD STYLE="width: 75%; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I, Donald C. Bradley
acting as registered Agent, in the State of Nevada and living in Clark County, Nevada, do hereby accept the full legal responsibility
as Agent for the corporation registered under the name of Ward&rsquo;s Futura Atomotive, LTD. who&rsquo;s address is, 5312 Ithaca,
Las Vegas, NV 89122.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify">/s/ Donald C. Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Donald C. Bradley</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: justify">STATE OF NEVADA</TD>
    <TD STYLE="width: 75%; text-align: justify">)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">COUNTY OF CLARK</TD>
    <TD STYLE="text-align: justify">)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SUBSCRIBED AND SWORN
to before me This <U>21<SUP>st</SUP></U> day of <U>October</U>, 1991.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify">/s/ O Chase</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">NOTARY PUBLIC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Residing in Las Vegas, Nevada</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">My Commission Expires: 2-4-95</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Filed in the office of the </FONT><BR>
<FONT STYLE="font-size: 10pt">Secretary of State of the </FONT><BR>
<FONT STYLE="font-size: 10pt">STATE OF NEVADA</FONT></TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 20, 1995</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLES OF AMENDMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PERFECT FUTURE, LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Articles of Amendment
to the original Articles of Incorporation of WARD'S FUTURA AUTOMOTIVE, LTD. a Nevada corporation are set up as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A. ARTICLE I -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the corporation
(hereinafter called the corporation) is PERFECT FUTURE, LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDMENT - ARTICLE I -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the corporation
is amended to: PERFECT FUTURE, LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">B. Article IV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total amount of
authorized shares is 50,000,000 having par value of .001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDMENT - ARTICLE IV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total amount of
authorized shares is 50,000,000 of common shares at a par of .001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of the
Special Meeting of Shareholders the Company had issued and outstanding TWO MILLION (2,000,000) shares of COMMON .001 par value
stock, held by 30 shareholders all of which were entitled to vote on the proposed amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VI PERFECT FUTURE, LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the Special Stockholders Meeting held
December 5, 1995, TWO MILLION SHARES voted in favor of the amendment and none (0) voted against the amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated this 5th day of December 1995</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Donald C. Bradley</TD>
    <TD STYLE="width: 15%">President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Donald C. Bradley</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Shaun Hadley</TD>
    <TD>Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Shaun Hadley</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STATE OF NEVADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COUNTY OF CLARK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 5th, 1995 Donald C. Bradley, personally appeared
before me a notary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">public, acknowledges that Donald C Bradley executed the above
instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">Signature of Notary</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">&nbsp;/s/ Kristina A. Heffner</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">STATE OF NEVADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECRETARY OF STATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF REINSTATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left">I, DEAN HELLER, the duly elected
Secretary of State of the State of Nevada, do hereby certify that <U STYLE="text-decoration: none">WARD&rsquo;S FUTURA AUTOMOTIVE, LTD. </U>a
corporation formed under the laws of the State of <U>NEVADA</U> having paid all filing fees, licenses, penalties and costs,
in accordance with the provisions of Title 7 of the Nevada Revised Statutes, as amended, for the years and in the amounts as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">1992-93&nbsp;&nbsp;LIST OF OFFICERS AND PENALTY</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">1993-94&nbsp;&nbsp;LIST OF OFFICER AND PENALTY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">1994-95&nbsp;&nbsp;LIST OF OFFICER AND PENALTY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">1995-96&nbsp;&nbsp;LIST OF OFFICER AND PENALTY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">REINSTATEMENT FEE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And otherwise complied with the provisions of said section,
the said corporation has been reinstated, and that by virtue of such reinstatement it is authorized to transact its business in
the same manner as if the aforesaid filing fees, licenses, penalties and costs had been paid when due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt">IN WITNESS WHEREOF, I have hereunto set
my hand and affixed the Great Seal of State, at my office in Carson City, Nevada, this 20<SUP>th</SUP> day of December, A.D., 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Dean Heller</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><I>Secretary of State</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><I>Deputy</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of the</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Secretary of State of the</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STATE OF NEVADA</P></TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">May 20, 1997</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CERTIFICATE OF AMENDMENT OF ARTICLE OF INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(AFTER ISSUANCE OF STOCK)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; text-align: center">Perfect Future, Ltd.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Name of Corporation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We the undersigned <U>Donald Bradley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">President or Vice President</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid">Shaun Hadley</TD>
    <TD NOWRAP STYLE="width: 2%">&nbsp;of</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; text-align: center">Perfect Future, Ltd.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Secretary or Assistant Secretary</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Name of Corporation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">do hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">That the Board of Directors of said corporation at
a meeting duly convened and held on the <U>22nd</U> day of <U>April</U> 1997, adopted a resolution to amend the original articles
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Article <U>IV</U> is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The corporation is authorized to have two classes
of stock:(1) Common ; (2) non-voting preferred. The total amount of authorized shares is 50,000,000 common and 5,000,000 preferred,
each class of which shall have a par value of $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of the corporation outstanding and entitled
to vote on an amendment to the Articles of Incorporation are 900,000, that the said change(s) and amendment has been consented
to and approved by a majority vote of the stockholders holding at least a majority of each class of stock outstanding and entitled
to vote thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Donald Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>President or Vice President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Shaun Hadley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Secretary or Assistant Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">State of <U>Nevada&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 112.5pt">ss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">County of <U>Clark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On <U>April 29, 1997&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, personally
appeared before me, a Notary Public, <U>/s/ Donald C. Bradley &amp; Shaun Hadley &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 58.5pt">(Names of persons appearing and signing
document)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 58.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Who acknowledged that they executed the above instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Claudia Hill</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature of Notary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Secretary of State of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STATE OF NEVADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 22, 1997</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT OF ARTICLES OF
INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(AFTER ISSUANCE OF STOCK)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center">Perfect Future, LTD.</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Name of Corporation</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%">We the undersigned</TD>
    <TD STYLE="width: 78%; border-bottom: Black 1pt solid; padding-left: 1.125in">Spencer Bradley Vice President</TD>
    <TD STYLE="width: 5%; text-align: right">&nbsp;and &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.125in"><FONT STYLE="font-size: 10pt">Name of Corporation</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; text-align: center">Shaun Hadley</TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;of</TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid; text-align: center">Perfect Future, Ltd.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Secretary or Assistant Secretary</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Name of Corporation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">do hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That the Board of Directors of said corporation at a meeting
duly convened and held on the <U>15th</U> day of <U>December</U>, <U>1997</U>, adopted a resolution to amend the original articles
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article <U>IV</U> is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The corporation is authorized to do a FORWARD SPLIT
of the issued and outstanding shares of two and one half for one. Making the total issued and outstanding 2,250,000 two million
two hundred and fifty thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of the corporation outstanding and entitled
to vote on an amendment to the Articles of Incorporation are <U>2,250,000</U>; that the said change(s) and amendment has been consented
to and approved by a majority vote of the stockholders holding at least a majority of each class of stock outstanding and entitled
to vote thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Spencer Bradley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>President or Vice President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Shaun Hadley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Secretary or Assistant Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">State of <U>Nevada&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">ss.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">County of <U>Clark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On <U>12/22/97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U>, personally appeared
before me, a Notary Public, <U>/s/ Spencer Bradley &amp; Shaun Hadley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 139.5pt">(Names of persons appearing and signing
document)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">who acknowledged that they executed the above instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Todd Fredlund</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature of Notary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of the<BR>
Secretary of State of the<BR>
STATE OF NEVADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 16, 1998</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT OF ARTICLES OF
INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(After Issuance of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PERFECT FUTURE LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We the undersigned Mark E. Bruk, President and Robert Harris,
Secretary of Perfect Future Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">do hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That the Board of Directors of said Corporation at a meeting
duly convened, held on the 11th day of June, 1998, adopted a resolution to amend the original articles as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Article I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The name of the corporation (hereinafter called the
Corporation) is PERFECT FUTURE, LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Article I is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The name of the corporation (hereinafter called the
Corporation) is amended to: EDUVERSE Accelerated Learning Systems, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of the Corporation issued and outstanding
and entitled to vote on an amendment to the Articles of Incorporation is ELEVEN MILLION TWO HUNDRED AND FIFTY THOUSAND (11,250,000)
common $0.001 par value stock, that the said change(s) and amendment have been consented to and approved by a majority vote of
the stockholders holding at least a majority of each class of stock outstanding and entitled to vote thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Mark Bruk</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Robert Harris</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Province of <U>British Columbia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">County of <U>Vancouver&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June <U>15</U>, 1998, personally appeared
before me, a Notary Public, Mark E. Bruk, who acknowledged that he executed the above instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Kesho Ram Ditta</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature of Notary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of the<BR>
Secretary of State of the<BR>
STATE OF NEVADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 19, 1999</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certificate of Amendment to Articles of
Incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For Profit Nevada Corporations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-size: 10pt">-</FONT> Remit in Duplicate &ndash;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation: <B>EDUVERSE Accelerated Learning Systems,
Inc</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The articles have been amended as follows (provide article
numbers, if available):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Article I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The name of the corporation (hereinafter called the
Corporation) is: <B>EDUVERSE ACCELERATED LEARNING SYSTEMS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Article I</B> is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The name of the corporation (hereinafter called the
Corporation) is amended to: <B>EDUVERSE.COM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power,
or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required
by the provisions of the articles of incorporation have voted in favor of the amendment is <B>7,571,134 (59.9%) of the 12,647,452
entitled to vote<SUP>*</SUP>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signatures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ Mark Bruk</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ Robert Harris</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>President or Vice President</TD>
    <TD>&nbsp;</TD>
    <TD>Secretary or Asst. Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(acknowledgement required)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(acknowledgement not required)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">State of <U>British Columbia</U></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">County of <U>Vancouver&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">This instrument was acknowledged before me on </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-size: 10pt"><U>May 18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </U>, <U>1999</U>, by </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-size: 10pt"><U>/s/ Mark Bruk&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>(Name of Person)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">as <U>President&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">as designated to sign this certificate</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">of <U>Amendment to Articles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(name on behalf of whom instrument was executed)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline"><U>/s/ Anthony K. Wooster&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Notary-Public Signature</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP></SUP></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;*</SUP> If any proposed amendment would alter or
change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must
be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority
of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting
power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMPORTANT: Failure to include any of the above information and remit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dean Heller,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SECRETARY OF STATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 10, 2001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Profit Nevada Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Remit in duplicate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 1.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of corporation: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eduverse.com.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The articles have been amended as follows (provide article numbers, if available):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-decoration: none; border-bottom: Black 1pt solid"><U STYLE="text-decoration: none">See attached &ldquo;Attachment A&rdquo; Amendment to Articles of Incorporation of Eduverse.com&rdquo; for Amendment of Article V.</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power,
or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required
by the provisions of the articles of incorporation have voted in favor of the amendment is <U>28,831,846&#9;</U>.<FONT STYLE="font-family: Symbol"><SUP>*</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 346.5pt">Against 13,404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signatures
(required):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">/s/ Grant Atkins</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">and</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ Grant Atkins</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>President or Vice President</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Secretary or Asst. Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol"><SUP>*</SUP></FONT> <FONT STYLE="font-size: 10pt">If
any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding
shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required, of the holders
of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations
or restrictions on the voting power thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMPORTANT: Failure to include any of the above information and
remit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ATTACHMENT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDMENT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLES OF INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EDUVERSE.COM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the provisions of sections 78.385
and 78.390 of the Nevada Revised Statutes, the undersigned corporation adopts the following articles of amendment to Article V
of its Articles of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;The aggregate number of
shares which the corporation shall have authority to issue is 50,000,000 shares of common stock at par value of $0.001 per share
and 5,000,000 shares of preferred stock at par value of $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Common Stock. There shall be no
cumulative voting, and all pre-emptive rights are denied. Each share of common stock shall entitle the holder thereof to one vote
at all meetings of the stockholders. Stockholders shall not be liable to the corporation or its creditors for any debts or obligation
of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Simultaneously with the effective
date of this amendment (the &ldquo;Effective Date&rdquo;), each share of the Company&rsquo;s Common Stock, $0.001 par value, issued
and outstanding immediately prior to the Effective Date (the &ldquo;Old Common Stock&rdquo;) shall automatically and without any
action on the part of the holder thereof be reclassified as and changed, pursuant to a reverse stock split, into any fraction thereof,
into 1/50 of a share of the Company&rsquo;s outstanding Common Stock, $0.001 par value (the &ldquo;New Common Stock&rdquo;), depending
upon a determination by the Board that a Reverse Stock Split is in the best interests of the Company and the Shareholders, subject
to the treatment of fractional share interests as described below. Each holder of a certificate or certificates which immediately
prior to the Effective Date represented outstanding shares of Old Common Stock (the &ldquo;Old Certificates&rdquo; whether one
or more) shall be entitled to receive upon surrender of such Old Certificates to the Company&rsquo;s Transfer Agent for cancellation,
a certificate or certificates (the &ldquo;New Certificates&rdquo;, whether one or more) representing the number of whole shares
of the New Common Stock into which and for which the shares of the Old Common Stock formerly represented by such Old Certificates
so surrendered, are reclassified under the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">From and after the Effective Date.
Old Certificates shall represent only the right to receive New Certificates pursuant to the provisions hereof. No certificates
or scrip representing fractional share interests in New Common Stock will be issued, and no such fractional share interest will
entitle the holder thereof to votes, or to any rights of a shareholder of the Company. Any fraction of a share of new Common Stock
to which the holder would otherwise be entitled will be adjusted upward to the amount whole share. If more than one Old Certificate
shall be surrendered at one time for the amount of the same Shareholder, the number of full shares of New Common Stock for which
New Certificates shall be issued shall be computed on the basis of the aggregate number of shares represented by the Old Certificates
so surrendered. In the event that the Company&rsquo;s Transfer Agent determines that a holder of Old Certificates has not rendered
all his certificates for exchange, the Transfer Agent shall carry forward any fractional share until all certificates of that holder
have been presented for exchange such that payment for fractional shares to any one person shall not exceed the value of one share.
If any New Certificate is to be issued in a name other than that in which the Old Certificates surrendered for exchange are issued,
the Old Certificates so surrendered shall be properly endorsed and otherwise in proper form for transfer. From and after the Effective
Date the amount of capital represented by the shares of the New Common Stock into which and for which the shares of the Old Common
Stock are reclassified under the terms hereof shall be the same as the amount of capital represented by the shares of Old Common
Stock so reclassified, until thereafter reduced or increased in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Preferred Stock. The board of
directors of the corporation is authorized to divide the preferred stock into as many series as the board of directors from time
to time may determine, and to issue the preferred stock in such series. The board of directors shall determine the number of shares
comprising each series, which number may, unless otherwise provided by the board of directors in creating such series, be increased
or decreased from time to time by action of the board of directors. Each series shall be so designated, as to distinguish the shares
thereof, from the shares of all other series. The board of directors shall have the authority to fix and determine the following
relative rights and preferences as of the shares of any such series of preferred stock (i) the rate of dividend, if any, (ii) whether
shares can be redeemed, and if so, the redemption price and the terms and conditions of the redemption, (iii) the amount payable
upon shares in the event of voluntary or involuntary liquidation, (iv) sinking fund provision, if any, for redemption or purchase
of shares, (v) the terms and conditions, if any, under which shares may be converted to common stock, and (vi) the voting powers,
if any.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#9;IN WITNESS WHEREOF, Eduverse.com has
caused these presents to be signed in its name on its behalf by Grant Atkins, its President, and its corporate seal to be hereunder
affixed and attested by Grant Atkins, its Secretary, on the 4th day of June, 2001, and its President acknowledges that these Articles
of Amendment are the act and deed of Eduverse.com and, under the penalties of perjury, that the matters and facts set forth herein
with respect to authorization and approval are true in all material respects to the best of his knowledge, information and belief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">EDUVERSE.COM</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Grant Atkins</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Grant Atkins, President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Grant Atkins</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Grant Atkins, Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before me, _<U>/s/ Stephanie Ebert</U>____________,
a Notary Public in and for the State of Washington, personally appeared Grant Atkins who acknowledged before me that he was the
President of Eduverse.com, a Nevada corporation, on this day, and that he signed the foregoing Articles of Amendment as his free
and voluntary act and dated for the uses and purposes therein set forth, and that the facts contained therein are true.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In witness whereof I have hereunto set my
hand and seal this <U>4</U> day of <U>June</U>, 2001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">My commission expires<U>&nbsp;&nbsp;9 09 03</U></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">/s/ Stephanie Ebert</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Notary Public</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dean Heller,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SECRETARY OF STATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 9, 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.380 &ndash; Before
Issuance of Stock)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>-Remit in Duplicate-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 1.25in; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of corporation:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eduverse.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The articles have been amended as follows (provide article numbers, if available):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Further Resolved that an amendment to the Articles of Incorporation of the</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Company to effectuate a change in name of the Company to &ldquo;Genemax Corp.&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">be and hereby is approved, and that such amendment to the Articles of</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Incorporation be filed with the Nevada Secretary of State.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned declare that they constitute <U>at least two-thirds</U> of the <U>incorporators</U> (check) ___, or of the <U>board
of directors</U> (check) <U>xx.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned affirmatively declare that to the date of this certificate, no stock of the corporation has been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signatures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">/s/ Grant Atkins</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Signature: Grant Atkins, President</TD>
    <TD>&nbsp;</TD>
    <TD>Signature</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT</B>: Failure to include any of the above information
and remit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid; padding: 0; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Filed
                                         in the office of</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Ross
                                         Miller</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Secretary
                                         of State</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">State
                                         of Nevada</FONT></P></TD>
    <TD STYLE="width: 20%; border: Black 1pt solid; padding: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font-size: 8pt">Document Number 20070220121-87</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font-size: 8pt">Filing Date and
        Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font-size: 8pt">03/29/2007&nbsp;&nbsp;&nbsp;&nbsp;3:40&nbsp;&nbsp;PM</FONT></P></TD>
    <TD STYLE="width: 25%; padding-top: 3pt; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">1.</TD>
    <TD STYLE="width: 1.25in; text-decoration: none">Name of corporation: </TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">GENEMAX CORP.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The articles have been amended as follows (provide article
numbers, if available):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Article IV is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;The corporation is authorized to have two classes
of stock: (i) common and (ii) non-voting preferred. The total amount of authorized shares is 200,000,000 common and 5,000,000 preferred,
each class of which shall have a par value of $0.001.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The vote by which the stockholders holding shares in the
corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power
as may be required in the case of a vote by classes or series, or as may be required by the provisions of the<FONT STYLE="font-family: Symbol"><SUP>*
</SUP></FONT>articles of incorporation have voted in favor of the amendment is: <U>75.5%.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="width: 62%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective date of filing (optional): <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Officer Signature (Required):&nbsp;&nbsp; <U>X /s/ Denis Corin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol"><SUP>*</SUP></FONT> If any
proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding
shares, then the amendment must be approved by the vote, in addition to the alternative vote otherwise required, of the holders
of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations
or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT:</B> Failure to include any of the above information
and submit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid; padding: 0; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Filed
                                         in the office of</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Ross
                                         Miller</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Secretary
                                         of State</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">State
                                         of Nevada</FONT></P></TD>
    <TD STYLE="width: 20%; border: Black 1pt solid; padding: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Document
                                         Number 00001403880-94</FONT></P>
                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Filing
                                         Date and Time</FONT></P>
                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">06/21/2007&nbsp;&nbsp;&nbsp;11:45
                                         AM</FONT></P></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; padding-top: 3pt; font-size: 10pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to Nevada Revised Statutes
Chapter 92A)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(excluding 92A.200(4b))</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name
and Jurisdiction of organization of each constituent entity (NRS 92A.200). If there are more than four merging entities, check
box <FONT STYLE="font: 10pt Wingdings">&uml;</FONT> and attach an 8 1/2 x 11&rdquo; blank sheet containing the
required information for each additional entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TAPIMMUNE INC.</B></FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of merging entity</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">NEVADA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Entity type*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Merging entity</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Entity type*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Merging entity</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Entity type*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Merging entity</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Entity type<FONT STYLE="font-size: 10pt"><SUP>*</SUP></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">and,</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENEMAX
        CORP.</B></FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of surviving entity</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NEVADA</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CORPORATION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Entity type*</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forwarding
address where copies of process may be sent by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger
&ndash; NRS 92A.1 90):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">c/o:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Choose
one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT><FONT STYLE="font-size: 10pt">
</FONT>The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.208).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*
Corporation, non-profit corporation, limited partnership, limited-liability company or business trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Wingdings">x</FONT>
The undersigned declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Owner&rsquo;s
approval (NRS 92A.200)(options a, b, or c must be used, as applicable, for each entity). (If there are more than four merging entities,
check box <FONT STYLE="font-family: Wingdings">&uml;</FONT> and attach an 8 1/2&rdquo; x 11&rdquo; blank sheet containing the required
information for each additional entity):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Owner&rsquo;s approval was not required from</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">TAPIMMUNE INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">and, or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">GENEMAX CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of surviving entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
plan was approved by the required consent of the owners of<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>*
</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">and, or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of surviving entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval
of plan of merger for Nevada non-profit corporation (NRS 92A.150):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The plan of merger has been approved by the directors
of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles
of incorporation of the domestic corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> Unless otherwise provided in the certificate of
trust or governing Instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each
business trust that is a constituent entity in the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">and, or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Name of surviving entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments,
if any, to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200):<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>*</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article I of the articles of the surviving
entity is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;I. The name of the Corporation (hereinafter
the Corporation) is TAPIMMUNE INC.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Location
of Plan of Merger (check a or b):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
(a) the entire plan of merger is attached;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">or,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Wingdings">x</FONT>
(b) the entire plan of merger is on file at the registered office of the surviving corporation, limited-liability company or business
trust, or at the records office address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
date (optional)<SUP>**</SUP>: 6/28/07</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signatures
&ndash; Must be signed by: An officer of each Nevada corporation; All general partners of each Nevada limited partnership; All
general partners of each Nevada limited partnership; A manager of each Nevada limited liability company with managers or all the
members if there are no managers; A trustee of each Nevada business trust (NRS 92A.230)<SUP>*</SUP> (If there are more than four
merging entities, check box <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> and attach an 8 1/2&rdquo;
x 11&rdquo; blank sheet containing the required information for each additional entity.):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> Amended and restated articles may be attached
as an exhibit or integrated into the articles of merger. Please entitle them &ldquo;Restated&rdquo; or &ldquo;Amended and Restated,&rdquo;
accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated
articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent &ndash; Nevada parent owning 90% or more of subsidiary), the
articles of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the
surviving entity may be changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>**</SUP> A merger takes effect upon filing the articles
of merger or upon a later date as specified in the articles, which must not be more than 90 days after the articles are filed (NRS
92A.240).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> The articles of merger must be signed by each foreign
constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this
page or as an attachment, as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT:</B> Failure to include any of the above information
and submit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%">TAPIMMUNE INC.</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name of merging entity</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">X /s/ Denis Corin</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">President, Secretary &amp; Treasurer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature</TD>
    <TD>&nbsp;</TD>
    <TD>Title</TD>
    <TD>Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name of merging entity</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">X</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature</TD>
    <TD>&nbsp;</TD>
    <TD>Title</TD>
    <TD>Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name of merging entity</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">X</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature</TD>
    <TD>&nbsp;</TD>
    <TD>Title</TD>
    <TD>Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name of merging entity</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature</TD>
    <TD>&nbsp;</TD>
    <TD>Title</TD>
    <TD>Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>GENEMAX CORP.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name of surviving entity</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">X /s/ Denis Corin</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">President &amp; Chief Exec. Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature</TD>
    <TD>&nbsp;</TD>
    <TD>Title</TD>
    <TD>Date June 13, 2007</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS PLAN OF MERGER (the &ldquo;Plan of
Merger&rdquo;), which has been adopted by the Board of Directors of GeneMax Corp., a Nevada corporation (the &ldquo;Company&rdquo;),
as of the 13<SUP>th</SUP> day of June, 2007, with respect to the merger of TapImmune, Inc. (&ldquo;SubCo&rdquo;), a Nevada corporation
that is a wholly-owned subsidiary of the Company, with and into the Company, is executed on behalf of the Company as evidenced
by the signature of the Company&rsquo;s President and Chief Executive Officer as set forth at the end of this Plan of Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors of the Company deems
it desirable and in the best interests of its shareholders that SubCo be merged with and into the Company (the &ldquo;Merger&rdquo;)
on the terms and conditions of this Plan of Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors of the Company, by
resolutions duly adopted, has approved and adopted this Plan of Merger as of the day first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is intended that the Merger be completed
pursuant to the provisions of Section 92A.180 of the <I>Nevada Revised Statutes</I>: Chapter 92A, as amended, (the &ldquo;Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the provisions of Section 92A.180(1)
of the Act, shareholder approval is not required by the shareholders of the Company or SubCo in order to effectuate the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATEMENT OF TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>The Merger</U>. SubCo will be
merged with and into the Company in accordance with this Plan of Merger and the applicable provisions of the Act and the Articles
of Merger substantially in the form of Exhibit A attached to this Plan of Merger (the &ldquo;Articles of Merger&rdquo;). Following
the Merger, the Company will continue as the surviving corporation (the &ldquo;Surviving Corporation&rdquo;) and the separate existence
of SubCo will cease, except insofar as it may be continued by the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Time of the Merger</U>.
The Merger will be effective at the time (the &ldquo;Effective Time&rdquo;) set forth in the Articles of Merger to be filed with
the Secretary of State of the State of Nevada, which filing is to be completed as soon as practicable following the adoption of
this Plan of Merger by the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of the Merger</U>. The
Merger will have the effects set forth in Section 92A.250 of the Act. Without limiting the generality of the foregoing, and subject
thereto, at the Effective Time all the property, rights, privileges, powers and franchises of SubCo and the Company will vest in
Surviving Corporation without further act or deed, and all debts, liabilities and duties of SubCo and the Company will become the
debts, liabilities and duties of the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Articles
of Incorporation: Bylaws.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The articles of incorporation
of the Company in effect immediately prior to the Effective Time will continue unchanged and will be the articles of incorporation
of the Surviving Corporation until thereafter amended in accordance with the terms thereof and in accordance with applicable law,
except that at the Effective Time, Article I of the articles of incorporation of the Surviving Corporation shall be amended to
read: &ldquo;The name of the Corporation (hereinafter the Corporation) is TAPIMMUNE INC.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The by-laws of the Company in
effect immediately prior to the Effective Time will continue unchanged and will be the by-laws of the Surviving Corporation until
thereafter amended in accordance with the terms thereof and in accordance with applicable law, except that any and all references
to &ldquo;GeneMax Corp.&rdquo; shall be deemed to be references to &ldquo;TapImmune Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Directors and Officers</U>. The
directors and officers of the Company immediately prior to the Effective Time will be the directors and officers of the Surviving
Corporation after the Effective Time and shall hold office until their successors are duly elected, appointed or qualified or until
their earlier death, resignation or removal in accordance with certificate of incorporation and bylaws of the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taking of Necessary Action</U>.
If after the Effective Time any further action is necessary to carry out the purposes of this Plan of Merger or to vest the Surviving
Corporation with full title to all assets, rights, approvals, immunities and franchises of either SubCo or the Company, the officers
and directors, or the former officers and directors, as the case may be, of SubCo, the Company and the Surviving Corporation will
take all such necessary action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBCO AND COMPANY STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion of the SubCo Common
Stock</U>. The one (1) outstanding share of SubCo common stock, par value $0.001 per share (&ldquo;SubCo Common Stock&rdquo;) issued
and outstanding immediately prior to the Effective Time will, by virtue of the Merger and without any action on the part of the
holder thereof, be converted into one (1) share of common stock of the Company (&ldquo;Company Common Stock&rdquo;) on a post-reverse
stock split basis (the Company is planning a reverse stock split on a two and one-half (2 &frac12;) old shares for one (1) new
share basis to occur at or around the Effective Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company Common Stock</U>. The
terms and conditions of the Company&rsquo;s Common Stock shall remain unchanged as a result of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Plan
of Merger will be governed by and construed in accordance with the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fax Exception</U>. This Plan of
Merger may be executed by delivery of an executed signature page by fax and such fax execution will be effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibit</U>. The Exhibit A attached
to this Plan of Merger if incorporated herein as an integral part of this Plan of Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, this Plan of Merger,
having first been duly approved by the board of directors of the Company, is hereby executed on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GENEMAX CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Nevada Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 40%; border-bottom: Black 1pt solid; font-size: 10pt">/s/ Denis Corin</TD>
    <TD NOWRAP STYLE="width: 60%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="font-size: 10pt">Denis Corin, President and Chief Executive Officer</TD>
    <TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to Nevada Revised Statutes
Chapter 92A)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(excluding 92A.200(4b))</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name and Jurisdiction of organization of each constituent
entity (NRS 92A.200). If there are more than four merging entities, check box <FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
and attach an 8 1/2 x 11&rdquo; blank sheet containing the required information for each additional entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><B>TAPIMMUNE INC.</B></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name of merging entity</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>NEVADA</TD>
    <TD>CORPORATION</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jurisdiction</TD>
    <TD>Entity type*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name of Merging entity</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jurisdiction</TD>
    <TD>Entity type*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name of Merging entity</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jurisdiction</TD>
    <TD>Entity type*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name of Merging entity</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jurisdiction</TD>
    <TD>Entity type<SUP>4</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GENEMAX CORP.</B></P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name of surviving entity</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>NEVADA</B></TD>
    <TD><B>CORPORATION</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jurisdiction</TD>
    <TD>Entity type*</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forwarding address where copies of process may be sent
by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger &ndash; NRS 92A.1 90):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c/o:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Choose one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.208).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP> Corporation, non-profit corporation, limited partnership,
limited-liability company or business trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Wingdings; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;The undersigned
declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Owner&rsquo;s approval (NRS 92A.200)(options a, b, or
c must be used, as applicable, for each entity). (If there are more than four merging entities, check box <FONT STYLE="font-family: Wingdings">&uml;</FONT>
and attach an 8 1/2&rdquo; x 11&rdquo; blank sheet containing the required information for each additional entity):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Owner&rsquo;s approval was not required from</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TAPIMMUNE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">and, or;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GENEMAX CORP.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of surviving entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The plan was approved by the required consent of the owners of<SUP>5</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">and, or;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of surviving entity, if applicable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Approval of plan of merger for Nevada non-profit corporation (NRS 92A.150):</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><SUP>5</SUP>
</FONT>Unless otherwise provided in the certificate of trust or governing Instrument of a business trust, a merger must be approved
by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">Name of merging entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">and, or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0">Name of surviving entity, if applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments, if any, to the articles or certificate of
the surviving entity. Provide article numbers, if available. (NRS 92A.200):<SUP>6</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article I of the articles of the surviving
entity is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;I. The name of the Corporation (hereinafter
the Corporation) is TAPIMMUNE INC.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Location of Plan of Merger (check a or b):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
(a) the entire plan of merger is attached;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">or,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;(b)
the entire plan of merger is on file at the registered office of the surviving corporation, limited-liability company or business
trust, or at the records office address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective date (optional)<SUP>**</SUP>: 6/28/07</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signatures
&ndash; Must be signed by: An officer of each Nevada corporation; All general partners of each Nevada limited partnership; All
general partners of each Nevada limited partnership; A manager of each Nevada limited liability company with managers or all the
members if there are no managers; A trustee of each Nevada business trust (NRS 92A.230)<SUP>*</SUP> (If there are more than four
merging entities, check box <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> and attach an 8 1/2&rdquo;
x 11&rdquo; blank sheet containing the required information for each additional entity.):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>6</SUP> </FONT>Amended and
restated articles may be attached as an exhibit or integrated into the articles of merger. Please entitle them &ldquo;Restated&rdquo;
or &ldquo;Amended and Restated,&rdquo; accordingly. The form to accompany restated articles prescribed by the secretary of state
must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent &ndash; Nevada
parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the
surviving entity except that the name of the surviving entity may be changed.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>**</SUP> </FONT>A merger
takes effect upon filing the articles of merger or upon a later date as specified in the articles, which must not be more than
90 days after the articles are filed (NRS 92A.240).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> The articles of merger must be signed by each foreign
constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this
page or as an attachment, as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT:</B> Failure to include any of the above information
and submit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TAPIMMUNE INC.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of merging entity</P></TD>
    <TD NOWRAP STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 26%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President, Secretary &amp; Treasurer</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of merging entity</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GENEMAX CORP.</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of surviving entity</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President &amp; Chief Exec. Officer</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed
    in the office of Ross Miller Secretary of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 0.1in; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document
                                         Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20070429826-20</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">06/21/2007 11:45 AM</FONT></P></TD>
    <TD STYLE="width: 65%; text-align: center; padding-right: 0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Change filed Pursuant
to NRS 78.209</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">GENEMAX CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The board of directors have adopted a resolution pursuant
to NRS 78.209 and have obtained any require approval of the stockholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The current number of authorized shares at the par value,
if any, of each class or series, if any, of shares before the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">200,000,000 authorized shares of common stock, par value
$0.001 per share; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">5,000,000 authorized shares of preferred stock, par value
$0.001 per share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">The number of authorized shares and the par value, if
any, of each class or series, if any, of shares after the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">80,000,000 authorized shares of common stock, par value
$0.001 per share; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">5,000,000 authorized shares of preferred stock, par value
$0.001 per share</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The number of shares of each affected class or series,
if any, to be issued after the change in exchange for each issued share of the same class or series:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">23,122,682 shares of common stock shall be issued
in exchange for 57,806,706 shares of common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">The provisions, if any, for the issuance of fractional
shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the
percentage of outstanding shares effected thereby:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">See Attachment A to this Certificate of Change</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.</FONT></TD>
    <TD STYLE="width: 2.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective date of filing (optional):</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6/28/07</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(must not be later than 90 days after the certificate if filed)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.</FONT></TD>
    <TD STYLE="width: 1.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Officer Signature: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X
    /s/ Denis Corin</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President &amp; CEO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT: </B>Failure to include any of the above information
and submit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20090099715-12</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">02/03/2009 4:34 PM</FONT></P></TD>
    <TD STYLE="width: 65%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TAPIMMUNE INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The articles have been amended as follows: (provide article
numbers, if available)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The number of authorized shares with a par value of $0.001
per share is 500,000,000 common shares and 5,000,000 preferred shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3:</TD><TD STYLE="text-align: justify">The vote by which the stockholders holding shares in
the corporation entitling them to exercise a least a majority of the voting power, or such greater proportion of the voting power
as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation<SUP>*
</SUP>have voted in favor of the amendment is: <U>50.33%.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 0.5in; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD NOWRAP STYLE="width: 3in; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective date of filing: (optional)</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(must not be later than 90 days after the certificate if filed)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid">X /s/ Denis Corin</TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> If any proposed amendment would alter or change
any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved
by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting
power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT: </B>Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20090531049-23</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">07/07/2009 10:45 AM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The articles have been amended as follows: (provide article
numbers, if available)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The number of authorized shares with a par value of $0.001
per share is 50,000,000 common shares and 5,000,000 preferred shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The vote by which the stockholders holding shares in
the corporation entitling them to exercise a least a majority of the voting power, or such greater proportion of the voting power
as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation<SUP>*
</SUP>have voted in favor of the amendment is: Not applicable per NRS 78.207</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 0.5in; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD NOWRAP STYLE="width: 3in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective date
    of filing: (optional)&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">7/10/09</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">(must not be later than 90 days after the certificate
    if filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 44%; border-bottom: Black 1pt solid">X /s/ Denis Corin</TD>
    <TD NOWRAP STYLE="width: 56%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Signature of Officer</FONT>&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Denis Corin, President &amp; CEO</FONT></TD>
    <TD NOWRAP></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> If any proposed amendment would alter or change
any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved
by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting
power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT: </B>Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20090531051-66</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">07/07/2009 10:45 AM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Change filed Pursuant
to NRS 78.209</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The board of directors have adopted a resolution pursuant
to NRS 78.209 and have obtained any required approval of the stockholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The current number of authorized shares and the par value,
if any, of each class or series, if any, of shares before the change.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">500,000,000 common shares, par value $0.001, and 5,000,000
preferred shares, par value $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">The number of authorized shares and the par value, if
any, of each class or series, if any, of shares after the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">50,000,000 common shares, par value $0.001, and 5,000,000
preferred shares, par value $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The number of shares of each affected class or series,
if any, to be issued after the change in exchange for each issued share of the same class or series:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This certificate is to enact a reverse stock split
whereby every 10 common shares currently outstanding shall be exchanged for one common share. The preferred shares shall not be
affected by this certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">The provisions, if any, for the issuance of fractional
shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the
percentage of outstanding shares affected thereby:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Any fractional common share that would exist as a
result of the reverse stock split shall be rounded up to the nearest whole share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 0.5in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7<FONT STYLE="font-size: 10pt"></FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 3in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective date
    of filing: (optional)</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">July
    10, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">(must not be later than 90 days after the certificate
    if filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3in; border-bottom: Black 1pt solid">X&nbsp;&nbsp;/s/ Denis Corin</TD>
    <TD STYLE="width: 0.5in"></TD>
    <TD>Title: President &amp; CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT</B>: Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20100108961-38</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">02/22/2010 12:15 PM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The articles have been amended as follows: (provide article
numbers, if available)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3:</TD><TD STYLE="text-align: justify">The number of authorized shares with a par value of $0.001
per share is 150,000,000 common shares and 5,000,000 preferred shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The vote by which the stockholders holding shares in
the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power
as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation<SUP>*
</SUP>have voted in favor of the amendment is: 55.6%.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 0.5in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4<FONT STYLE="font-size: 10pt">.</FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 3in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective date
    of filing: (optional)</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2/22/10</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">(must not be later than 90 days after the certificate
    if filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid">X /s/ Denis Corin</TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>*</SUP> If any proposed amendment would alter or change
any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved
by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting
power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT: </B>Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20140007739-73</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">01/06/2014 1:55 PM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Designation For</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.1955)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">By resolution of the board of directors pursuant to a
provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations,
preferences, limitations, restrictions and relative rights of the following class or series of stock.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Please see the attached Certificate of Designation
for the Series A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 0.5in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3<FONT STYLE="font-size: 10pt">.</FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 3in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective date
    of filing: (optional)</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">(must not be later than 90 days after the certificate
    is filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">X /s/ Glynn Wilson</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filing Fee: $175.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT</B>: Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TapImmune Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 78.1955 of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada Revised Statutes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_____________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SERIES A CONVERTIBLE PREFERRED STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On behalf of TapImmune Inc., a Nevada corporation (the &ldquo;Corporation&rdquo;),
the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Corporation
(the &ldquo;Board&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RESOLVED, that, pursuant to the authority granted to and vested
in the Board by the provisions of the articles of incorporation of the Corporation (the &ldquo;Articles of Incorporation&rdquo;),
there hereby is created, out of the five million (5,000,000) shares of preferred stock, par value $0.001 per share, of the Corporation
authorized by Article III of the Articles of Incorporation (&ldquo;Preferred Stock&rdquo;), a series of Series A Convertible Preferred
Stock, consisting of one million, two hundred and fifty thousand (1,250,000) shares, which series shall have the following powers,
designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations
and restrictions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The specific powers, preferences, rights and limitations of
the Series A Convertible Preferred Stock are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designation; Rank. This series of Preferred Stock shall
be designated and known as &quot;Series A Convertible Preferred Stock.&quot; The number of shares constituting the Series A Convertible
Preferred Stock shall be one million, two hundred and fifty thousand (1,250,000) shares. Except as otherwise provided herein, the
Series A Convertible Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu
to the common stock, par value $0.001 per share (the &quot;Common Stock&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends. The holders of shares of Series A Convertible
Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds
legally available for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation Preference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any dissolution,
liquidation or winding up of the Corporation (a &quot;Liquidation&quot;), whether voluntary or involuntary, the Holders of Series
A Convertible Preferred Stock shall be entitled to participate in any distribution out of the assets of the Corporation on a five
(5) to one basis per share with the holders of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A sale of all or substantially all
of the Corporation's assets or an acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent
(50%) or more of the outstanding voting power of the Corporation (a &quot;Change in Control Event&quot;), shall not be deemed to
be a Liquidation for purposes of this Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting. The holders of Series A Convertible Preferred
Stock shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote
of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. There
is no right to cumulative voting in the election of directors. The holders of Series A Preferred Stock shall vote together with
all other classes and series of common stock of the Corporation as a single class on all actions to be taken by the common stock
holders of the Corporation except to the extent that voting as a separate class or series is required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion of Series A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Automatic conversion. Upon the occurrence
of a reverse stock split of the Corporation's common stock in which every 100 shares of the Corporation's common stock outstanding
at the time that this certificate of designation was filed with the Secretary of State of Nevada is exchanged for one share of
the Corporation's common stock, each share of Series A Convertible Preferred Stock shall automatically convert into five (5) shares
of the Corporation's common stock (such number to be after the aforementioned 100:1 reverse stock split), subject to adjustment
as provided in this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Fractional Shares. No fractional
shares of Common Stock or scrip shall be issued upon conversion of shares of Series A Convertible Preferred Stock. In lieu of any
fractional share to which the Holder would otherwise be entitled, the Corporation shall issue a number of shares to such Holder
rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series A Convertible Preferred
Stock by the Corporation upon conversion of Series A Preferred Convertible Stock by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Dividends, Splits, Combinations
and Reclassifications. If the Corporation shall (i) declare a dividend or other distribution payable in securities, (ii) split
its outstanding shares of Common Stock into a larger number, (iii) combine its outstanding shares of Common Stock into a smaller
number (other than the 100:1 reverse stock split referred to in Section 5(a)), or (iv) increase or decrease the number of shares
of its capital stock in a reclassification of the Common Stock including any such reclassification in connection with a merger,
consolidation or other business combination in which the Corporation is the continuing entity (any such corporate event, an &quot;Event&quot;),
then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share
of Series A Convertible Preferred Stock will equal the number of shares of Common Stock that would otherwise be issued but for
such Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issue Taxes. The converting Holder
shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common
Stock on conversion of shares of Series A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF the undersigned has signed this Designation
this December 24, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">/s/ Glynn Wilson</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Glynn Wilson</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Chief Executive Officer and Director</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 15%; border: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">Filed
                                         in the office of</FONT></P>
                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"> Ross Miller</FONT></P>
                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">Secretary of State</FONT></P>
                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">State of Nevada</FONT></P></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 0.1in; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20140117253-36</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">02/18/2014 2:33 PM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center; padding-right: 0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center; padding-right: 0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Change filed Pursuant
to NRS 78.209</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The board of directors have adopted a resolution pursuant
to NRS 78.209 and have obtained any required approval of the stockholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The current number of authorized shares and the par value,
if any, of each class or series, if any, of shares before the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">150,000,000 common shares, par value $0.001, and 5,000,000
preferred shares, par value $0.001 (of which 1,250,000 have been designated as Series A and 1,500,000 as Series B).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">The number of authorized shares and the par value, if
any, of each class or series, if any, of shares after the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">150,000,000 common shares, par value $0.001, and 5,000,000
preferred shares, par value $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The number of shares of each affected class or series,
if any, to be issued after the change in exchange for each issued share of the same class or series:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">One share to be issued for each 100 shares of common
stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">The provisions, if any, for the issuance of fractional
shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the
percentage of outstanding shares affected thereby:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Any fractional shares shall be rounded up to the nearest
whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.</FONT></TD>
    <TD STYLE="width: 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective date and time of filing (optional):</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(must not be later than 90 days after the certificate is filed)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X &nbsp;&nbsp;&nbsp;/s/ Glynn Wilson</FONT></TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: President</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT: </B>Failure to include any of the above information
and submit the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20140118418-40</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">02/18/2014 4:22 PM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Designation For</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.1955)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">By resolution of the board of directors pursuant to a
provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations,
preferences, limitations, restrictions and relative rights of the following class or series of stock.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Please see the attached Certificate of Designation
for the Series B Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 0.5in; padding-bottom: 1pt">3.</TD>
    <TD NOWRAP STYLE="width: 3in; padding-bottom: 1pt">Effective date of filing: (optional)</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>(must
not be later than 90 days after the certificate is filed)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-decoration: none">X &nbsp;&nbsp;&nbsp;&nbsp;/s/ Glynn Wilson</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filing Fee: $175.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT</B>: Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TapImmune Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 78.1955 of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada Revised Statutes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SERIES B CONVERTIBLE PREFERRED STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following resolution has been duly adopted by the board
of directors of the Corporation (the &quot;Board&quot;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RESOLVED, that, pursuant to the authority granted to and vested
in the Board by the provisions of the articles of incorporation of the Corporation (the &quot;Articles of Incorporation&quot;),
there hereby is created, out of the five million (5,000,000) shares of preferred stock, par value $0.001 per share, of the Corporation
authorized by Article III of the Articles of Incorporation (&quot;Preferred Stock&quot;), a series of Series B Convertible Preferred
Stock, consisting of one million, five hundred thousand (1,500,000) shares, which series shall have the following powers, designations,
preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The specific powers, preferences, rights and limitations of
the Series B Convertible Preferred Stock are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designation; Rank. This series of Preferred Stock shall
be designated and known as &quot;Series B Convertible Preferred Stock.&quot; The number of shares constituting the Series B Convertible
Preferred Stock shall be one million, five hundred thousand (1,500,000) shares. Except as otherwise provided herein, the Series
B Convertible Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu to (i)
the common stock, par value $0.001 per share (the &quot;Common Stock&quot;) and (ii) the Series A Convertible Preferred Stock,
par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends. The holders of shares of Series B Convertible
Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds
legally available for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation Preference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any dissolution,
liquidation or winding up of the Corporation (a &quot;Liquidation&quot;), whether voluntary or involuntary, the Holders of Series
B Convertible Preferred Stock shall be entitled to participate in any distribution out of the assets of the Corporation on a seven
(7) to one basis per share with the holders of the Common Stock and a one and four tenths (1.4) to one basis with the holders of
the Series A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A sale of all or substantially all
of the Corporation's assets or an acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent
(50%) or more of the outstanding voting power of the Corporation (a &quot;Change in Control Event&quot;), shall not be deemed to
be a Liquidation for purposes of this Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting. The holders of Series B Convertible Preferred
Stock shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote
of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. This
right is equal to that of the Series A Convertible Preferred Stock There is no right to cumulative voting in the election of directors.
The holders of Series B Preferred Stock shall vote together with all other classes and series of common stock of the Corporation
as a single class on all actions to be taken by the common stock holders of the Corporation except to the extent that voting as
a separate class or series is required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion of Series B Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Automatic conversion. Upon the occurrence
of a reverse stock split of the Corporation's common stock in which every 100 shares of the Corporation's common stock outstanding
at the time that this certificate of designation was filed with the Secretary of State of Nevada is exchanged for one share of
the Corporation's common stock, each share of Series B Convertible Preferred Stock shall automatically convert into seven (7) shares
of the Corporation's common stock (such number to be after the aforementioned 100:1 reverse stock split), subject to adjustment
as provided in this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Fractional Shares. No fractional
shares of Common Stock or scrip shall be issued upon conversion of shares of Series B Convertible Preferred Stock. In lieu of any
fractional share to which the Holder would otherwise be entitled, the Corporation shall issue a number of shares to such Holder
rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series B Convertible Preferred
Stock by the Corporation upon conversion of Series B Preferred Convertible Stock by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Dividends, Splits, Combinations
and Reclassifications. If the Corporation shall (i) declare a dividend or other distribution payable in securities, (ii) split
its outstanding shares of Common Stock into a larger number, (iii) combine its outstanding shares of Common Stock into a smaller
number (other than the 100:1 reverse stock split referred to in Section 5(a)), or (iv) increase or decrease the number of shares
of its capital stock in a reclassification of the Common Stock including any such reclassification in connection with a merger,
consolidation or other business combination in which the Corporation is the continuing entity (any such corporate event, an &quot;Event&quot;),
then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share
of Series B Convertible Preferred Stock will equal the number of shares of Common Stock that would otherwise be issued but for
such Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issue Taxes. The converting Holder
shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common
Stock on conversion of shares of Series B Convertible Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20140123643-86</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">02/20/2014 1:03 PM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Amendment to Articles
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.385 and 78.390 &ndash;
After Issuance of Stock)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The articles have been amended as follows: (provide article
numbers, if available)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The number of authorized shares is 500,000,000 shares
of common stock and 5,000,000 shares of preferred stock (the terms of which are to be determined at the sole discretion of the
Board of Directors), each class with a par value of $0.001</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The vote by which the stockholders holding shares in
the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power
as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation<SUP>*
</SUP>have voted in favor of the amendment is: 278,685,000 of 428,685,000 (65%)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4<FONT STYLE="font-size: 10pt">.</FONT></FONT></TD>
    <TD STYLE="width: 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective date and time of
    filing: (optional)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(must not be later than 90 days after the certificate
    if filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">X /s/ Glynn Wilson</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>*</SUP> </FONT>If any proposed
amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares,
then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares
representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions
on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT: </B>Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid"><FONT STYLE="font-size: 8pt">Filed in the office of Ross Miller Secretary
    of State State of Nevada</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Document Number</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">20160405751-11</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Filing Date and Time</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">09/13/2016 2:00 PM</FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificate of Change filed Pursuant
to NRS 78.209</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Nevada Profit Corporations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Name of corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The board of directors have adopted a resolution pursuant
to NRS 78.209 and have obtained any required approval of the stockholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">The current number of authorized shares and the par value,
if any, of each class or series, if any, of shares before the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">500,000,000 authorized shares of Common Stock, par value $0.01
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">5,000,000 authorized shares of Preferred Stock, par value $0.001
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">The number of authorized shares and the par value, if
any, of each class or series, if any, of shares after the change:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">41,666,667 authorized shares of Common Stock, par value $0.001
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">5,000,000 authorized shares of Preferred Stock, par value $0.001
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The number of shares of each affected class or series,
if any, to be issued after the change in exchange for each issued share of the same class or series:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">One (1) share of Common Stock will be issued in exchange for
every twelve (12) shares of issued and outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">The provisions, if any, for the issuance of fractional
shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the
percentage of outstanding shares affected thereby:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All fractional shares of Common Stock will be rounded up to
the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7<FONT STYLE="font-size: 10pt">.</FONT></FONT></TD>
    <TD STYLE="width: 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective date and time of
    filing (optional)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;September 16, 2016 Time</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(must not be later than 90 days after the certificate
    is filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Signature: (required)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">X /s/ Glynn Wilson</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: center">Chairman and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMPORTANT: Failure to include any of the above information and
submit with he proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Glynn Wilson, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2016 of TapImmune
Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Based on my knowledge, this Report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting
in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this Report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of the internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the
registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&#9;November 4, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><I>/s/ Glynn Wilson</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">By:</TD>
    <TD STYLE="width: 93%; text-align: justify; padding-left: 0.125in"><B>Glynn Wilson</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Michael J. Loiacono, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2016 of TapImmune
Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Based on my knowledge, this Report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting
in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this Report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of the internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the
registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&#9;November 4, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><I>/s/ Michael J. Loiacono</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">By:</TD>
    <TD STYLE="width: 93%; text-align: justify; padding-left: 0.125in"><B>Michael J. Loiacono</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: left">Title:</TD>
    <TD NOWRAP STYLE="text-align: left; padding-left: 0.125in">Chief Financial Officer and Chief Accounting Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND PRINCIPAL ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, Glynn Wilson, the Chief
Executive Officer of TapImmune Inc. (the &ldquo;Company&rdquo;) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune Inc., for the quarterly period
ended September 30, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition
and results of operations of TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in">November 4, 2016</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.5in"><I>/s/ Glynn Wilson</I></TD>
    <TD STYLE="width: 60%; padding-left: 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Glynn Wilson</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND PRINCIPAL ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, Michael J. Loiacono, the
Chief Financial Officer and Chief Accounting Officer of TapImmune Inc. (the &ldquo;Company&rdquo;) hereby certifies, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune
Inc., for the quarterly period ended September 30, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material
respects the financial condition and results of operations of TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in">November 4, 2016</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.5in"><I>/s/ Michael J. Loiacono</I></TD>
    <TD STYLE="width: 60%; padding-left: 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Michael J. Loiacono</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer and Chief Accounting Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ /,# 2(  A$! Q$!_\0
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MP *XR_\ '=E-=0V5M"TD$\@C-PYVJ>?X1U--)O83:6YO#7L_\NK?G2_VX?\
MGV/YU%]DP2,=*46OM2&;$3^;$CX^\ :DKA-7\?P>%-<ATW6;22.RF0-!>)\R
M^X8=L5V5E?6NHVB75G.D\$@RKH<@TW%I78E)-V+5&***0PQ1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q2'J!2TT_?% #J,444 )1110 M%%% !1110 4444 %%%%
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M39[Q;4VXBE,>TMG/O5?PWX\LM>UV^TAHC;7=NY"*S9$H'4BL'X+_ /(MW_\
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MMDY^3/4>F:F%2/+>6\=ARIRYK1V>YF_%RQATSPYH%E;J%BAF"*!["NG\?_\
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M3@H\\GO0!5NX?,N8P<X]JD_L^W_NG\ZDF^\#WIOF-ZT[L5B:.)8T"KT%+W%
2Z"C^(5)0ZBDS1F@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pg1img1_10q.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_10q.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5 "K P$1  (1 0,1 ?_$ +P   $#!0$!
M       '" D" P4&"@0! 0 !!0$! 0               P0%!@<" 0@0   %
M 04&! ,%!@4$ P    $" P0%!@ 1$@<((1,4%18),4$B%S(C&%%A<1D*@9&Q
M0C,DH6*R0W/!T?%2-$24$0 ! @0$ @<%!04&!04    !$0(  P0%(3$2!D$3
M46&1(A05!W&!H3(6\+'!T4)2<B,S%^'Q8K)3-(*2TD,DLU0E-2;_V@ , P$
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M&(6S%NN[$RRJ5^$03QWFLV=;)LT$RV/>T$A6@D8=:>_V0AY_)!1SF@]9 /\
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M.9I_B9]]>;JRP7Y<$B5V1RO-JGQ"\SFNSZ-6&75[X?'W0/9OZ#]2WO9?[=]
MN^?\JX/FG&;U'E7#8/3S+B]U@Q;;O"TCL3Q?UE1?-X76U55$U'4B]Y$3+W1Y
MZI^%\OF9J@^7IQ1=7!(YM*WX?\J3M?>Y7N?PGU$P?MISO@NI^E^;'Z:YUO\
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M;WQ\K_'9;XZ]1O+OKG_\DGT[A\NK2B'_ %?XF<?2OI]YE]+L\R7G*[/2N?\
*APB7VT3%NC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg18img1_10q.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg18img1_10q.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!EP)C P$1  (1 0,1 ?_$ 0   0  !@,!
M       $!08'" D! @,* 0$  04! 0$              P$"! 4&!P@)$
M!@(! 0,#"@T*$ P"!PD! @,$!08 !P@1$A,)(9,4,='35)055946%U&1(M)C
MU5:6UE>7&%A!,B,S0[,TM'4984*2LE-S@R1TA+7%-G9W"O!Q@;%2<L,UMC?7
M."6WH6)$9-1%984FP4;&)V>'>!$  0," P,&"0<(!@<'! ,! 0 " Q$$(1(%
M,1,&05%AD=%2<2(RDE,45!4'@:&QTC.3%\%"<K(C<U46\&(TE-0VX<)#HR1T
M5O&"L\,U=95C@[0(HF1V)?_:  P# 0 "$0,1 #\ R<M3YZ%ILX ]>  6.<
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MRGIS[VZ\]U+^R8W47=;U!-[+WG=95W=4/7HQ^Z>KQV/9T=:3%ZN5A[)@M5&
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M:S.2T.(P<&EU<7925ZKI_#%EK7"V@P1AD&H7^K3POG# Y^0!V4'%I<&TP;F
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MGB5S6M:UP:0!&&AM*"M:XDD+&K.T7')A$PB81<95#L5X-U?Z14[_ &+Z2_\
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M, #D-Q;7HMY"Z]O'-#'8&5Q!P.!%<0>520&QWS,MG:-=F%"(V@@UV@TVCD4
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MB6 %K<*4VA3^I<]KY7-0ZR=Q&JKIR%M-IU-OW>$Q,678%$H\M$4O36UIZLV
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M;NFRI4CCG50\:W!XH@X7OK)MK=R0L>XR7# <SVN<6VXR9;G=D99"Q[7 G!I
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M$H& >O4(I)6Q%H<'',X 4%:5Y3S#I5[&%]2"!E%<33JYST*[XAT_5+T$0 !
MQ1 W:_6]@>O0W:Z>3IUZY(K%V$AR]OJ40[LP$4#]5,X]1 B@>J0X@4?(/0?(
M.$5K([=FI9;<EEX\QM^@GF[Z=1H39EHUFB+[Y1PE!LCX(R"M#OMLB1AH^2?&
M*F0J;@ZY1,43IE*8IAC$L9E, (WH;4CH/*K]V\,$A'[,FE>GF5U!3.'>=2B
MI& JH=/*D8PB!2JAZJ9A$!  -T'J&2*Q=,(F$3")A$PBTI^(-_[G*Q_L!B?_
M )C6S/H'X-?V&\_>C]5J^??C-_ZA9_N3^L]8>9[2O%DPB\A70!<C47" .E$C
MKIM172!TH@F<J:C@C83]^=!-0X%,<"B4IA !'J(93,W-DJ,Y%:5QISTVTZ57
M*[+FH<E:5IA7FKLKT+V$HE'H8!*/T! 0'Z0Y=LVJBXRB( ]! 0_4'K]+*HL2
MV/"32\=9=A6B->;>9%VH_P!B2M[JK/;ET0UW/2>TXF0A+G(N*(B\)7!?/&,D
M?N53(F4;*)(G(/5$G3C(^ M"BNKF[B=>M%XZ9TL8N91"]UPUS97&(')4AQH:
M5:0"/)"Z^3CC6Y+6WM96V;O5&PMBD-O&9F-@<'1@2D9Z MQ%:.!<#M*])SA/
MQ[L5:4J4K7; K"*Z/IG'4Z*5LE4%QU70;0RN59B?22#W@2C6>CTE%'W[<LF
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M^K'NE^93C=[XE:EM3[ L-RW'%:OKJ+R2AZE:D6#2.TO9*#*(.2RS:Q$:N%5
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MZA:>JQ/DI":Y033QG+!M>S5EXW<M')W3IHZ;+MGC9:NV%5!PT<I&0<H.$S1
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M0$,AS>#'C*]MBYIMA;4+6D>K@U$-"/L@0"&; 0"-B@:_B]AS,=?-<+DW%07
M[\BAFJ#]H02"[:02.54@30?$=.A/-6DTAKDNNI">2M+VFAK.0]Y'%F0:$8(V
M$Z PO>A-(QY ;D<E."I6X=T!@)U+F$-+^'HTYVD"WT[W8Z3>&+(W(7@4#Z;<
MP& =6M,-F"S#J?'IU!NJF?4/>38\@DS.S!A-2RO=)QRTI7':HIQI#B>ZL$):
MW&DM:JV6M-:RRKTX.JURR,*UI0-"T].-7)7R^BGK";! C%0H HV22*F0P$#L
MY>[3OA^^YCO'0::;N)L88_(S,P14W>4TPW= &':T  &F"L;J'';+=]HV?41:
MREY>W.^CC)7>9A7'/4EXV.)).*J+9VO^/>ZDXE+;VN*GLHL"JY6A#7*@2<TM
M$G>]WZ:$>X<PHN&R3SN2=\F4X)JB0HF*(@&9.K1\%ZZ&#6FV-UNR2S>AKBVN
MVA(J*T%16AIBL?2Y.,-$+SH[KVVW@&;=ES0ZFRH&!I4T.T<BCJK4M%45A9(J
MDT"IU&)N1&Z=LB*WKIW#1%C3:Q P""<Q%,:^C'/4RP@BU$IDNAT1$I@'J/62
MS=P?I\<L-@+&"&>F\:QK6M?1N09F@ 'Q?%V8C J.['%E_)%+?&]FFAKNW/+W
M.95V<Y7$DCQO&VX'$*C:_H[B?4X*6K%8TIKF!KT]+P<]-P\7J]VU9RTS6'I9
M*MR#\I(+O'*U?D" NR QA(V5#M)E*(CUP;;3OA_9V[[2T@TZ.VD>Q[VM8T!S
MHSF8XX8ECL6\C3B LVXU#CN[G9=74^H27$;',:YSGDM:\4>!CAG&#N4C J=M
M=9<;F.R'^XF>JZ.VVK*'>JR.PDM:NRVIXO)-C,I)TO*>\/>F>R+,QDG"_D67
M3,8IS& QNN0R#@>/5':VR.P&L/KFFRMWA+A1Q+J;7# G:034XJ!\_&;]-;HS
MWWYTEE*0YG[L!IJT!M=@.(&P'8, J<B=!\18!M964'HO640SN44X@;8UCM5N
M&J%B@G4JRG5X2622@2D=0YYF.;N@:B'<$61(8I2],Q8=+^'ELR6.WMM-8R=A
M9(&L8 ]A<'ECL,6YFAV78" 0%DS:GQ]<.B?/<:B]\#P^,E[R6.#2T.;C@[*2
MW-M()J5=R+-K:#G[#:X:(:15GMI().TS["IS;:6L*=79*1M;),/4X<%GQ8*/
M6.BU XCW*1A*7H YNH;_ (<M[F6\@DMF7<V3>/% Y^[&5F8[3D!(;78, M/+
M9<0SV\=I/'<OM8<^1A!+69SF?E&P9R*NIM*I%G0N/L>C4V['7-2:(4*=G[12
M44-?2)$ZI8K8=PK:)F"+[Q]&#ZQJ.U3/C$\CD3CW@&S"8W@R,0MC;8M;;R/D
MB :W]F^2ID<S# OJ<]/*KC59CW\7R.F=(Z]<ZXC8R6I=^T9'3=M?SAE!E[M,
M%3%=T9Q.J,==8BKZ4US 1.R(X8>^QD9K%XWC[9#BX%W[T3#,(,6Z\45X/?%;
M%*1$BW0Y2@< $,2UTWX?64<\-I!IT<-TW+,UK&@2-K7*X4H6UQRX"N-*K*N=
M1X[O)()KJ;4))K9V:)SG.)C=2F9IK4.IAFVTPK11S'3W%Z.>MGT?IW7Z#YM1
MCZO;KIZP=**_-VLV,R4I*H*0"A7=>49G%$6ZH*%%(>Q^M\F7LL^ HGB5D.G!
M[;?<5R,^PI3=&HQ93"AKAAL5C[SCB5AC?+J!8;C?TS/^VK7>BAP?7&HICCM7
M6I:=XOT%@QBJ5J.CU>.B[C';"CF</KN3:IL;U#LW4=$6QL/O,91*=B6#U9!J
MN!NTW15.1/LE,(8LK+@/3HVPV$6GPQ,G;,T-:T4E:"UL@_KM!(:>0$@8%+R\
MXWU"1TM]+?RR.A,)+BXUB<071G^JX@%PY2 3BJH"J:.+.'LX4BO!8C7EML\\
MY\AI;WS'8K*(5@6EY,\&&[WY4-8-8[0CSKWI6YA)UZ".9F?A'UCUL>I^M>L"
M?/09M\&Y!+7T@82T.VTP6+EXKW'JO_&>K;@P9?&R[DNSF*G<+@'%NRN*Q>W;
MX>^E=^.X*>@IE+7\(G2[G52P-?H&O;=4W#38T^-GM-QK\3=(211J.R)63,)C
M3S("OB] Z=#%ZCSFO_#;0N(WQW-N\6T&XECR,AADC(G?O))6-E8X1SN=_MF4
M<N@T/XB:WP^R2WG8;B??QR9GRS1R PLR,C>Z-PWD+6_[)WBK.:H5EA2JC5*7
M%+R#J+I]:@:K&.99T+Z5<Q]=BFD0R<2;T2)B[D%FS,IEE>R7MJ"(] Z],] L
MK2.PLH;"$N,,$3(VEQJXM8T-!<>4D#$\I7"7EU)?7DM[,&B6:5\C@T4:"]Q<
M0T<@!. Y KRZ:TU=N15V7I-)75@Z[!JMQV7LL6X+LJ6R7 %2PD(54/1Y;8,L
MWZ^BM>HILDQ](<="@4I^-XUXUM>&;4PPD/U1X.5M=G2>8#E/R#'9V7!?!=UQ
M/="20%FEL(SOIMZ!SD\@^4X+?AK+65)T]2877NO85*#K$&D<$$ .+AZ_>N!!
M20FIJ04#TB6G99QU5=.E1%150?U"@4I?EN^OKK4KI]Y>/+[AYJ2?H',!R!?4
MEA86FF6C+*R8&6[!0 ?23RD\I_(J\S$68F$3")A$PB81,(F$3")A$PB81,(F
M$43^X?XM_G#+?S_E_P!57<GR?E4JM<W%5B.M5GG798^"K,?8;)./S)++%80L
M"T>RTL^,@V36<K%9Q[-102)D.H?L]"E,80 :-(;$''8&@_,C@2\@;2?RJT7'
M;D+J+E=INE;_ -"VE2[ZGV&WDW53LJL%/UM:03AIJ1KTF1:#LT;$SD>LSF8I
MPB8J[<@F%/M%[1!*8;8)H[B(30FL;MAV='*JRQOA>8Y!1XVJ7[MY+Z<X[3.C
MJ_MJQ2%?E.1NXH'0NI$&5>F)PD]L^RMG#J&A9!:*;.$X%DY2;&[3UV*;9,W0
M#&#KU!+/%"6"0T+W91TD_0JQQ/E#BP5RMJ? NO);DYI#A_JUUNGD1<CT#6S.
MRU:H.+ 2O62SJ$L-SDRQ%>8A$52)F9@Y7;P1[:H("DBF0QU#% /+2>XBMH][
M,:,J!6A.)V;$BBDF?DC%7TKU>%-8<F=-[DVSR!TAKVQ2$QL?B]-TBO;HB'%>
MF8ME7938E><VFII1LP_:H1]B1?PK-1111F=0J!R]@_0PAU1SQ2R/B8:OC(#N
MBHJ$?$]C&R.'BOK3Y%!N.5_'YER#M?%J1V*QBMVT;2R/(:W5N7C)J*A:_IY6
M4&(-<I*\R$>WI#9LT==#N$32 .&[<064(5/J8'K$(F-N74E#,Q',WGKL5=S)
MNA-3]F74'A\&U7OKMBK]P@8:TU&>A;75[%'MI>O66M2K">K\]$O2 JSE(6:B
MG#N-E8YVF/:2705424+Y2F$,E:YKFAS2"T["-BC((-#@5.1 0$0$! 0]4!#R
MA_QAE51! 0\@@(#] 0Z81<812-E5ZQ&3DY:(VLUR-L]G2C4+-9H^"BF5BLB$
M*B=O#(6&=:M$I6;1AVZADVA'2JI6Q#"5,"@(AE UH)< ,QVGE/A5:DBA)H%/
M,JJ)A$PB81,(F$3"*>V'^%L/Y KW^2&F8UK]F[][)^L5//Y3?T&_JA?%'*<"
M-K<\^6_BAT36FCN.L,6'\4NHV:;YVWBU SW[H>)I+2MVF6HFI*C$5-U:)Y"R
ML6X*=KW[8L/25A*HF4X Y2YYUG+>7<[8VM%)ZYSM%*&@PK7F\8 U.!I4;47#
M+>")SW.^R\D;#MQ.-/F*N\?D++Z:3YS56I;DWMJ*Y[[\>;D_KZN?,(]X[5"U
M7;T33E'F'T+/[HY0+I:JTK6XQ06[YQ*J J^>*)%:(E AU5"3&?<"8-<]KG7;
MQXN6IHT&E78#Z3L"LW8DW9+6N:VW:<<V&)Y&XE8TI[QWKRMUMX(W(+?/.:ZZ
M4?*<S^7NC)7>Z)M'L652<4M*<84O;4Q99&!'6LGL"7K#A*NKNUBGA7S1,KA)
M/OU#K*8IGFN6VSY9,I#G#-XO]8 G BM!2N(-=G/-NXX73QQQAWB--,>BH'+3
MEYU<NH\A^8]%@4]/:SY3RE3O^S?]X4V3PKN_(5GI_2*-VO6O'FMZY#?+&[UZ
M"I$-4;9>A>K%E0D'")G"KU)(JBQVY"IY.V>Y8W=,DH]UZ6%V5M2* 5( H3RJ
M,QP..=S*M%L' 5- :\F-:*_U4YV<JM)DU72MS\MY"PTS3GCTW+@SMO?FQX^A
MU%S>N-$5KI"T147M^:&-0K\.G[Z/515DDCLCIE2 HK@F0H%F;=W$65DLE6MO
M#&YQH*MI7QC^51F"*2KF,HYUOG &-'5Y%1T?S[Y@<@RUZ%TGS.E*S!;F\>_:
MO#:@;DJ54UO>6,;Q1=:T:2E1B*>REZ\I V"+BQ?&D8A\OWJJKCN53KK) !36
M^NW4P AEIFO"P$ 'Q*8 8=15?5X8ZF1E2VW#B*D>-7%4%K#E[XBU5:5O:UDY
MUWK9M=T9XV,1X8DGK2UZTU>UB=S:>F[6]82UZVA/0<*RG)#88,GR3=B=!1-%
M@DV*<@F6ZG&R.YOFTD=,7-9=;JA \85VG#;]"O=#;&K!& 709Z@G \PZ%]D*
MY 2763+U$J:JA $?5$"'$H=?Z/0,Z9:1>6$3")A$PB81,(F$3"+L50Y0Z%.<
MH=>O0IA .OT>@#ZN*!*JH(-57NK!^RJ>2N/1#ZLWJ^F1W]',6Y K%^]'T.4T
M1-'_ +L_2%(>^5_LJG]6;U\RJ!15*=\K_95/ZLWKXH$J4[Y7^RJ?U9O7Q0)4
MIWRO]E4_JS>OB@2I3OE?[*I_5F]?% E2G?*_V53^K-Z^*!*E.^5_LJG]6;U\
M4"5*=\K_ &53^K-Z^*!*E.^5_LJG]6;U\4"5*=\K_95/ZLWKXH$J4[Y7^RJ?
MU9O7Q0)4IWRO]E4_JS>OB@2I3OE?[*I_5F]?% E2G?*_V53^K-Z^*!*E.^5_
MLJG]6;U\4"5*=\K_ &53^K-Z^*!*E.^5_LJG]6;U\4"5*=\K_95/ZLWKXH$J
M5.*ZLK\H(+]E4_[XC/Z<WMU#^CF/= >JR?NW?05+;D[]GZ8^E2QPLKZ0X_95
M/V];^G-_93?T<F:!E'@'T*-Q.8^%0;M97T1Y^RJ?P-W_ $YO:ZO]'+V@9AX0
MK'$Y3X"OEGHG^AU>_D\/W];/MO2__38/W3?H7Q'J?_J,_P"]=]*O9IG3ETY&
M7AQ1J0Y4@Z] G;'V9LKT<KAG2V#D.VG"0A% ]'E=@2Z #Z*V$139)CZ2XZ%
MI3\EQKQK:\,6ABB(?JCP0UO-TGF Y3\@Q76\%\%W7$]V)) 6:8P@O=3;T#G)
MY!\IPV[\]9ZSI.GZ3"Z]U]"I0=8@TC@@@!S.'K]ZN(*2$U-2"@>D2T[+..JK
MITJ(J*J#^H4"E+\MWU]=:E=/O+QY?</-23] Y@.0+ZEL;&UTVU9963 RW8*
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M +MUK7E#8Z1KN5/6FZVZ%'L39K2]0KGH#MDT;[.8(+QDXW1;IG=0LDX;)F2
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M*\_A4GK%P7[PO=O *5KC3F541/$#BE ZF::%A>-6CXK2+&RL+FVU,RUG54*
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M>TL> 6$4(*N:YS'!["0X' K9_P %^=#JA.:]Q^Y!6%9W3W2K2"U#M^>=BHO
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MN.Q7]W?XXW##CWM+;&K=@UCD\Y1X];;J^EN1&WJOH25F=$Z2M%S3@B5.:O\
MLLD^2*BJS9WDYW3/NP7D3':K]6O9! R]WK<>.!R@C'DQY^;YU:('D5PJ>E63
MU1XLBNM-E^)X;E+8[#?*AI?Q#]><1.'NM-1:Z@YW9=XD]D4UY(U/5='CH4L"
M-WGYYW%K/BOIF0*5) BIC.2D[M,8F73\QW@-*T IC7##P[5>Z$4&6FS''Y_
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MRJ<E8&LW6&<E&2JC!5N15N]25*0RC<I<L?:E[7U)J7$CYNGY.3:KVSY2TTP
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MN^*^(=1T=\DNJ;F&RU^QC-P&V]3%,P/)F=;R& LB=4N:UQ8\59*<*#$M>%]
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MRM;0483^<6\_R5(%3E1G.+HDPB81,(F$3")A$PB81,(F$3")A%Z_TO\ <_\
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MN7JU,(F$3")A$PBPX\0O_P!D');_ %#BO_'M.SJ."/\ ..F?\T/U'KEN-_\
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M]#E-%L?^[/TA2',E0IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$4^JO\
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M1[5%-N?/+9H5V5*2TD(/6:C%;M:VL8]$55$53"3I?2]#]I .@CU#IU\F6/\
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MOUW [)I>S+/.WC9.M]C[028/Z6O!I1$5'U[6DY$3!2RGODH"BIB*D(8"B(D
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M#_F7KUA9]K1P4C:[Z@:14M##9^[XZKQKO5=7L%/II[Q.5M=T2>"UN))"*[M
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MI&Y@@ED=Y9-6E[6R?[1C7 .V5 H!/)QI<7.F0V5]9V4]_;P;F&Z>UQGCC'D
M4<&.='_LWN:2WF)Q-N8CPYM;,H"0J<WM7<%RK$=J'9&CM30]E?5-0FDZ!M5
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M,&*1E',AI!LR(HX,F_>*B*8:WGGO][L6ZJ@+LWR@$; =$QB$\ ^*7"^EV/\
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M,4XYMZ^V)LVU(3LMM"Q[$K-,,[V-.OJ#8ZC48VY2NI(FPI5$62P.FL?Z8DY
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MUYJATRRE:XDRYB&R7 H!E#&[TBA-,@=4*;2>$[?1>([236';R&TTT:C>1N:
M(\H+HX#4G,7NW0((%<]*%6==\K;]QGY:;3C-CWU_*<.]8G::1C825;1RSFK6
MZ$XVUK;%)E%;"=H%ADY>_N*]*QX^DNEC+/'0"/41+V=(_C'4>%>,KR/5+AS^
M";2EJUC@TF.1MDRXB=GIG<Z8LD9XSC5SO!3<LX2T_B?A"TETRW:SC*ZK<N<T
MD"2-UX^WE;DKD:V(/C?XK11K?#6'X_<ON2=9UYO::W?/4&Q["8;DU-7JE7=G
M3CRBP5.:;8U<ILI.D0[77E!MMUN<S">FH,B1S..=/51146,H1--3K;PWQKQ3
M::;J$^OR6TNIMOK=D;)WF)D0N+??[IHAADEE<RH:&-8YYH7$@ J[B'@[AJZU
M*P@T..XCTYUE</D? T2OD-O/N=ZXS2QQ1M=0N+W/:T5#:$D*X8>*(VB=:5G9
METU4RKT1>M&;6O%%$EN>*I6C<^HM@N*%-:?:^E5]JZ;MYSM-)!@[,F+P&ZYB
M*-N\3'KLOQ;;#I46JWUFV*&XT^XEB_:$[RZMIC"ZV%6 @/\ %>QU,V4D%E0M
M<?A6^74Y=+LKLR36]_!%+^S W=M<0B5MP:/();XS'MKEJ 0ZA5=3'.S9,'(S
MTZ_T37T-5:PVGJ716Z9E38SL+Y!;5V7'5E>42I=6+5SQ\_5J5*6A%JHJ[=M'
M3_L&.D1, ,!-A/\ $+5+>62XET^,:/:7EO:73M\=\RXG:PNW4>[ROCB=(&DN
M<USZ$@#&F!#P%ID\4=O'?R'5KJTN+JV;N1NGP0%X;O9,]622M87 -:YK*@$G
M"MQ>0UFVG:>4>C>+E%VO,Z3@;AKC9FU+E<Z9'5Q]L"Q#3'S6%B:35'=KC)J*
MB"=^N=^[5(T6<*-TC '9(4>UM.);O5[SBW3^$=/O)+"VGM9[B66)K#,_=$-;
M%&9&N:W$YW$-)(',,=;P[:Z3:<*W_%5_:,OKB&Y@@CCD+Q$S> N=+((W-<[
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MWAV[F^0.QZY![<D2M(8REYC#TJV/YIF\32CP0:%2EHY$RQF1&YTE$P*(EZB
M\Q9<1ZS-HG"-VZX<Z?4KIC+AU&_M6[J0N!PH/&:*Y<M"%T=YP]H\6L\5VK8&
MB#3K9[K<5=^R=O8PTC&I\5QIFK4%3_G/=][ZTM]$O4=8]V4[BO TR>7VS<^/
MD)0+%;Z5>#3K!*!L]]A[I$R[N4UBQAE!](19%2 3][VU ,"939/Q!U#B'2KV
MWU&*6_@X0C@>;B6S;"^2*7. Q\S96N+H W:&TQK4UHL?@2PT'4[.XL)(K&;B
MN2=@MX[MTK(Y8LA+V1.B<T-G+MA=7"E!2M-B\?(-).'CYB.=IOV$G#LY:.D$
MRB1-^R?QZ3]B^(F8I#)D>-UB*@42E$ -TZ!ZF>G12LEA;/$0Z-[ YIYP6U!^
M4$%>;R1OBF=!(,LC7EKAS$&A'R$$+2EI_?').M:BX9\E+?R LFSVG(C?*&G;
MOI>W5>A,X96&G[K=:PE.:ZEJY78BSM9NK-JNDY.555RB?OA!3HG]0;P?1.(>
M*;31=#XIO=2ENV:GJ(MI;62.$-ROEEC#H7,8V0/C$8<:EP-<<,#[?K.@<,W6
ML:UPS9Z?%:OTW3S<17,;Y2[,R*)^69KWN86R%Y:*!I%,,<5W:[SY(.N+E5Y]
MAR!LJB]@W9#PX<=4:[1OFA3HLKNE75PZ_$"0(7$]O:PY1>J2'O@9R!RC^Q_4
M]YE6<0<4/X1A^(WO*4NDOVM]2#(O5MRZZ]7W/D;W>!OC%^?-7DY51V@\--XK
ME^'WNZ++'8N=ZX7R^L;UMMO][Y6[W9=XH9DRTY>1=[;N[DQ5*!RHY0Q_(2Q.
M(_C_ ,S[CJ.$T3/56A.=>7*@15YJ==:4]"11KK6YH6E9C:SBV61?'4ZM \G4
M3*!6]U[BJSTW6.+8]2E,>FZ[);LM'QPF&6%LL;!$'!@E$A$GBD/KXOA*I::'
MPQ>:AI/"LFG1B34-$CN'73))1-'*Z*1YD+2\QF,&/Q@6T\;Y%NV W;*4_=G2
M[PA%.Z4_;$NV4#]TIY _9$^O9-_1#/>JUQV5^9>'TH:;5SA43")A%,ZG5+GL
MZ[1.L-91:4Q=YI/TM55V"@0%-KY52I/+E<720"+*%8=KHDD'[._7[**("8WD
MYSB;B6PX:L'75TX&4CQ&<KCR8?TYSABNCX:X:O\ B6_;:6C3NJ^.[D:.4D]'
M^@8D!;YN/O'VE<=J4-8JXK2\[+K)2=ZO4FDD6PWBP%2[!I"0,3M SC&8&%-@
MP3'T=BWZ%* G$YS_ "CKNNW_ !!?NOK]Q+B?%;R,',/RGE\% /J[0=!L.'K!
MMC8M  \IW*\\YZ.8<GA))OMFF6Z3")A$PB81,(F$3")A$PB81,(F$3")A%$_
MN'^+?YPRW\_Y?]57<GR?E1[_  UY_A;G]_4Q']FW]$?0C_*/A*ALN5J81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3"*>V'^%L/Y KW^2&F8UK]F[][)^L5//Y
M3?T&_JA?'IR(\7WEIJ;EGR;J4'R=H4:CIWQ!:)QPU]Q@O/&"(+K:UZ4LKR"8
MV&V7OEX4M?C=7/Z^:15[/OG+%=+]GO"AW8?4Z.?4KJ.Z>QKVY6S90TMP(PVN
MY.7::]!Y-E%90OA8XL/C1EQ<'8UZ&\O4MQ=@\6[6M;W7S"US)\>]\IZJX)C=
ME.2')EJE4WVIZDC7J"G>:<SBT2RJ$]8K%M%QWD1%1R"8+I/>X46$J#@#I[(Z
MI$)9(W,>&QUS'#"@KLK4D[*<G*L(63S&QP<W/)3*W&IQI\VU4?HGQDJ3O!;:
MM7:<8MP16X*+H6K\G:-IJN[&T%L^Q;>TQ;;''U=K+1EGIFPUJ1KVV5=]+-U[
M)!V1\Q>0+ QW"PF!(Y,1:HR7,W=N$H8'!M6G,TFFT&@(Y0=BK)8NCH<[<A<6
MDT(H1X14CF(VJ@U?';TG Z@Y$WF_:+OU0V=QNVII'45LT^PVKHZ^0DM/\B6\
M@\U;/L.0E0M[[2<;1E6L0[&9E7<@1"&4;BFIWBA@*%AU>)L;W/8X/8YH(JTB
MKMGC TIMJ>2BN]WR%[6M<"QP)!H1LVX4K7FYUVVAXI7)VL<M/#LTM5>$-F?4
M[E]K[<-PND AL/3=YN!G%&%P@D;5VS:9M%?5TC7]?QC9&S3KXWIJ$Q 2;5.-
M.5X1PFFDU"X;<P1-B.65I)Q!.',0:4&T\X(HC+2(PR2&09F$ 8$#'G!%<=@Y
MCM5Y?$;Y*\EJMO[A'P9X@W&E:KV_S-L>WG\UON[TEML6/U3JG2-4:V6TRE9H
MTJY:1,];YOTP2M"/ 42*#?NQ!,5O2$);V>=LT5I;$-EE)\8BM T5-!SJRUBB
M,<EQ,"6, P!I4GI47L'DARB\/O2%>;\@X>5\0.[K2.R)]]N^DEX_\-Z?":\J
MS2%E(R%OZ>S-B153<;2=(O'I(R,KQ'KF;2:B)4R*$-VSY[BRB&^!F?CXPRL%
M.FII7FIM1L45S(=W^S;A@:NQ/-0;/#L5M+!XT])?-]#-]$<1N2?(NT<B>'LG
MS2I55I3K75?>P&MJS9)VNW:-OKVQ6$&<'(5,U9>G,X:C()2#CT9HT(JN[2#(
MG:O%1FZC>]SX\XV"@K2AJ=O@K4T Q*N%@[QMX]K0U^4[=O0I^;QBJ3>"<;(C
MC%Q9Y!\J=D<A>-GYW#[56OWVN*M:]3:+2L*M.<S%L=W6RQ\%-6I>X,G<?'Q$
M>X.I)'; 9)7]G0*>_P!YL?D$$;Y'O9GH* ANRIJ=M<*<JIZDYN8RO:QC7Y:F
MN)VX4Z%+[YXU^A:+R L6H5-6WZ8UWKW>]#XQ[6WHA=]11B5#W=?U8ADC7V^D
M)6XM]U76KTV9FD8^PSL5&*LHYZ4Y" N!2&4H_5H63[G*XL#@TNJ,'&F%*U-*
MXGZ55MC(Z,/!&8M+@*'$#II0= 60?%+Q#F7+O>>\=24/C3O.N4OCWL3<>GM@
M<@[5\E$]3'VUJ&YMJPK0:\LPDG$S,2]FB''OPF)42D8-1(DX_95 Z3V]Z+F9
M\;(WAC"X%QI2K32@\.U136QAC:]SVES@" *UH1M_(MBV9JQDPB818(>) LBV
MXNR"[A9)N@CM'4*BJZZA$44DRW5B)CJJJ&*FF0H>J(B !G;?#L@<76I. &;Z
M%Q'Q%!/"-R!B:M^E:8!ME4ZC_P#O17/5'_\ /8O_ /%Y]7^L0>D9YP[5\H;B
M?N/\T]BX^5E4^ZBN?'L7_P#B\>L0>D9YP[4W$_<?YI[$^5E4^ZBN?'L5_P#B
M\;^#TC/.':FYF[C_ #3V*RM]U!QKVA>879-]BJ79+I7Z3;==14R[M(I C3+S
M'2<39X5=@TF6\:](^CYEVDFLLDHX:@Y4% Z8F$<T.HZ!PUJVH1ZIJ,4,M_%!
M)"UQ><(I6N;(T@.#35KG $@EN8Y2*K>:?KO$6E6#],T^66*RDGCF<T,&,D1:
MYC@2TN%"UI(! =E&8&BM[6...C:+;N/SVC6:NUG6O&Z V4WUYJQ&91DV2=TV
M8<B$G?9"RS%B?2KZ4CXA=ZW0(N190#OE%.^+T @ZVTX3T33[W37Z>]D6E:7'
M.(;<.S#>SX.F+W/+BYK2X &IJ\G-R+877%.LW]IJ++]CY=3U.2$S3D93NH<6
MQ!C6!H:7!I)%!1H&7E55W70?%C8S783*[0E0L#7:MUI6Q+ZB[NCPA)RXZ\BV
ML)4I</1I]$8WWNB&A6RB#3N&[M$RA5R* H?M9E_PQPKJ;+F._ABE9>3Q33 R
M.\>2%H;&[!XRY6C*0VC7"H<#4UQ+'B7B?37VS[&62-UI!+#%2-OBQS.+I&XL
M.:KCF!=4M-"TB@I!W'CQQ:O3NT2<ZVC$)JW[%K6VI:PU[9\]5["VV'4J_P#)
M2"LE?F8"T,'U6<-JV)F9TXX[9!9,YA.03CVPCON%.%=1?++<, GFNF7#GLG?
M&\31LW;'L<QX,9#/%(86@@FHKBK[+BCB:P9%% \F"&V?;M8^%CV&&1^\>Q[7
ML(>"_P 8%^8@@4-,%:K8W$#05MK7&W6]6F*-4-4Z!W4;<*E8<S*]CEIL>]E9
M=Q68V>F+"[=LX^P6>3](DS.CN>]12(1,"B4,U&I\"Z!>VNEZ7:&&'1].O_6<
MA<7N=Y3C&U[GD@/D=F?FS5  %%M]-XVURTN=3U.[$TVK:A8^KYP QK?):'EC
M6 $L8VC,N6A))JKGV#C=Q-M.V5-V3T+6W]]<S\);I$X[!ED*I-7&M(E;URX3
MU#;V5*F35H@DB@#9XX9**$-]4/:/]5FVN>$N$KO63KUQ$QVHF1LCOVKQ&Z5F
M#)7PA^Z=(S\USFDC;M6JM^*N*;72!H<$KVZ>(W1M_9-,C8WFKXV2EF\:QWYS
M0X [-F"J3=>GN.?(5"NDVJ6#F7]/?.Y&IV.&OKVGVZMN9%(B$F6'M54GHB<:
M-91!,I7* +"BMV2B8O:* AE:]P_PYQ*V(:PULDD#BZ-[971R,+L'99(WM> X
M>4*T/*%C:'KW$'#KI#I+G,CF:!(QT;9(W@8MS1R-<TEIV&E1SJEV?&CB-'M'
M+%E UELT>--2LG*)-BSA^_0T;-*V'6 J*K6I5<R]?F5SKJJB85)$QA!X9<OD
MS$9PAPA&PQQPQACA;@_MGXBT<7P?[2M6.-2=K_S\P64_BSBN1XD?,\O:;@C]
MDS;=-R3_ )E*/:  -C/S TJI&.E^-,8O%.6+*M(+PNW+GO:-.%Y?'!#:NP8^
M1BK=:3$4L!B+^^S"673]#4 S%#M@9)$ABE$,J/AWAJ)S'QQQAT=[+=M_:NPN
M)FN;))Y>.8.(RGQ!7Q6B@6,_B#B*5KVR2/+7V<=J[]FW&"$AT<?D892T',/'
M/*XU*H1?B;PX6'6(D@(-D.H:^SJ5*-%;2LT2H%2CI]2TQ]6LZT=;FRUVK[*Q
MJF>)M98SQ,%3" ]2")!USN">#'>J$0M;ZE$(XLL\C?V;7[P1R%L@,K _Q@V3
M,*]&"SV\9<7M]:K,YWKDADES0QN_:%F[,C*QD1/+/%+H\IITXJLMS:.XU;]E
MH2P[-",?V.OQ\E"QUDK>RYJB6 :[,G,I,5A_+TNS03V4K4F<YA69.#*(#VS]
MD"B<W7.USAOAKB.:.YU5H==1-<UKV3/A?D=Y49=$]A<QW*UU1B:4J5A:+Q%Q
M%P_"^WTMQ;;2.#G,?"R5F=ODO#9&.#7MY'"AP',%/]/:RX^:"A9NM:A1K%,K
M,_+$FWU;;7-Q*02$B$>A&+*14;.SLHA#H/6[<IG*+;NT7"XF54*90YC#DZ)H
MO#_#D$EKHC(X+21^<L$A<P.H&G*U[G!H('C!M 34D5)6/K.LZ[Q!.RZUA[Y[
MJ-F4/,8:\BI<,SFM:7$$^*75(% #0*V^N.*_#W4M[8;'H5?KL/98-:=<51)S
MLB=FJU1G%H*L2QKT.GS=ID*S3UIHCA0JYV+5(W9.8I!(41#-7I?!?!NC:@W5
M-.A8RZC+S'69[F1&2N<PQOD,<9=4U+&C;A1;+4N,.+M7L':;J$SWVL@:)*1,
M:^4,ID$LC6!\@;04S..S&JD<KPVX6S<568*1A&BL%56#V(:0B>Z+TWBIF%D+
M-*7)Q"7!DC>B)7&("S33ITFC(]^"0JBF402 $\QYN N"9X8K>6&MO"TM#?69
M@US7/=*62 2_M6YW.< ^M*T'BX*>'CCC*"66>*:D\K@XN]7A+FN#&QAT9,7[
M-V1K6DLI6E3CBL@Z?6]-4&9OD]47=;AY+9DS%S]S,2V@Z:24G"P+6LQ9V<<]
MEW$?!-6<&R2;E;L$FS<2D 1()O+G2V5CH^G3W%S9;MDMW(U\OCU#G-8(VT:7
M%K & #*P-&&RJYZ\OM6U"&WM[PO?%:L<R/Q "UKGE[JD-!<2XDU<7'IHK)ZR
MXH<-=06B#N=$K-<9V.JK2#BH/)S9UGN#6F.951RK).J;#6VXS4)5W3Q1XJ)U
M639%3J<1 P"/7-#I/!7!>B7D=_IT#&W4)<8R^:201%U<QB;)(YD9-3BUH.*W
MFJ<9<8:S:R65_.]UM* ) V&.,R!M,HD='&USP*#!Q(P4.TXC<+V.Q4]H-JK5
MB6%"VC?VL.;8<TKKUE>Q6])"Y,=9*6<]$:V$CO\ 9B+$8 5-;]D*4#^7+&<#
M\$QZF-69;Q^LB;?!N^?N1-6N]$&?<A]<00S X@55S^->,7Z;[J=/)ZN8=T7;
MIF^,5*;LSY-Z64PH7XC FB]D^)O#(NPWNTG-6K,K;G]Y?[-<!.[+LLY50V%)
M.ROG=Q1H4I<'5'1GC.R%4*L6/ZIF*7L@'9+TN'!/!7O-VKNMXWWKK@SG/-(^
M/?.-3*(72&(/KC7)AA38%:>,^,/=S=*;.]EFV 0#+#&V3<M%!&96QB4MIA3/
MCRK*TUNJHB)C6FNB(B)C&-/18B(CY1$1%WY1'.P]8@](SSAVKD]Q-W'^:>Q3
MENX;NT4W+1P@Z;K%[23ALLFN@J7J(=I-9(QTU"]0]4!')&N:X9FD%O.,0HW-
M<TY7 AW,<%[9544UJ=3NFS;I%:SUG%)35WF4O2SG=BH2 J$ 10J3RXW%XD4P
ML8-B)NB:8?L[Y?LHH%,8WDYSB7B6PX:L'7=VX&4CQ&<KCR8?TYS@NBX;X;O^
M);]MI9M.[KX[^1HY23_3F%2M\''KCU2^.M,-6ZV96:L4TJC)WV^R2*9)^[3Y
M$NP+QX).T#&(8@84X^/3-W#)#R!VCF44/\I:[KU_Q#?NOKYQ)).5M<&#F'3S
MGE\% OJ[0= L.';!MC8MY!F=3%YYSS#F')TFI5^LTJW:81,(F$3")A$PB81,
M(F$3")A$PB81,(F$43^X?XM_G#+?S_E_U5=R?)^5'O\ #7G^%N?W]3$?V;?T
M1]"/\H^$J&RY6IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(I[8?X6P_D"O?
MY(:9C6OV;OWLGZQ4\_E-_0;^J%H>W%X+2VZ+1RNA9KFUMVM<8>:F_8;D%R X
MT534VKD"VBPP+B!>1T*RW)+J2]V@XTCJN-1,=HW1[1$P 4Q-U,;"ETH2OD+I
M7"&1^9S0T5Y#0.V@8#J"R&7V[:RC 96-H'5/T;.592H>&CJ=Y6O$<HEKN%EL
M-$\1ZPM)FZP36-8PS[5K2.UZTH44PJ$RJ]F??UY$*,&\DV>/&Z0@X0(11)0H
M&,;(]0C+9V.)+)SCT84P^E1>M/!B<T .B&'3C58AQ'@FG=<:=Z<9=@\I(.5K
M>U]24O4E;M.I>&''+CY<*RTH=QKMQB[)L"RZZ9I6O=DA-GJK-A,LI63;1\FT
M%515,71P<%QFZ32!\#Y*M<T"H8UI%"#B1B=F(K13&_\ VK96,Q:XG%SB,13"
MNSH4PU5X--ETW6^38TKEK5V5_P"5CC1QMDK'X-\;3:&5A-,1-K@U:&7C()3:
MT5I-T86- [DB16DDW>QQ'/I:RJRPC6/2S$V3+(,\F6OB-R^+7#+LH:^'I1]\
MUY9F8<K*T\=U<:8YMM0HVA^"U'Z<J' AII+EGL37>S>"ERW;88K92FL:%9F.
MPZWR1EVTEN:@EUU*.B5J@UZ49HGCX@&AWGO2U74.!57/87)5FEB)L(BD<V2$
MN-: U#O*%-@'(.94=?%YDSL!9(!A4X9=AKR]/.LQN<W!",YBR&C=CT_<EYXR
M\CN,-TGKMH'?.O8B"M4G4'%LC$(:V5JP5.T 2)M]1LD<T0(Y:*K("?NNR8RB
M*JZ"N3=V@NLCVN,<\9JUPQI7:"#M!4%O<;@.8YH?$\4(/+18;;S\'>_<C6^B
M[%N?GA<-K;AU,ANR"L&P=K<9=#["J5DI^]8F#@Y^+I.EYEL77^K+'38^# :[
M--TY!TQ=.#N#$,H4@!B3Z6ZY##-,YTC:XEHQ!I@!L%*=/+4$8+(BOFPEPCC
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MV=BG<-IG3:B<Z)]0:I,*4 [53$VN*6/84*[8% Y?_@GD, &$.O\ 1S&N-0U
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M=/\ XH]5_DXIGVDQZ_?^GG^\?VI[OL/00?=L[$^9W3_XH]5_DXIGVDQZ_?\
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M2''9$WO?!QX',G'1Z9NY9H?])0RBA_G/7M>ON(;]U]>N.TY6UP:.8=/.>7P
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MY_S)\W\!\)3GFH['O2Y[D?6Y/4(>\_YD^;^ ^$ISS4=CWI<]R/K<GJ$/>?\
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M<+)7"<JD<I*.&[5+ZHYE2D&XO>]AD&;(7C;7R14;=OA_TJC6M:X,P+@T]?\
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MS***'$"$(43"( &1R/9"QTDI#8V-)<2:  "I))P  Q). "OC8^5[8X@72.(
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MR,VH^WAO?B9IG:VVY2)BX24OEOKJ[V9E&,$*'O$I)IMW[6-D):"2;)I,I%9
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MW#<-+*5+X'9V@U!\4G!U*&FPA>9:+K5SH<\T]JUCGSVDUN[-6@9,W*XBA'C
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M0<&N>22YYS.<<SB?&QIT*\8B(CU$1$1]41'J(_\ +F\6E3*(N/I^J @("("
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:;^SM_A#^VY9F&;EV\Q[O@5U#3DV<XYU__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
